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°C degrees Celsius 
3’ three prime end of DNA sequences 
5’ five prime end of DNA sequences 
A adenosine 
a.m. ante meridiem 
ACTH adrenocorticotrophin 
AgRP agouti-related peptide 
AKT proteinkinase B 
ALS amyotrophic lateral sclerosis 
AMPK AMP activated protein kinase 
ARC arcuate nucleus 
BAT brown adipose tissue 
BBB blood brain barrier 
BMI body mass index 
bp base pairs 
C cytosine 
c DNA concentration 
CaCl2 calcium chloride 
cAMP cyclic adenosine monophosphate 
cDNA complementary DNA 
CLAMS Comprehensive Laboratory Animal Monitoring System 
cm centimeter 
CNS central nervous system 
CNTF ciliary neurotrophic factor 
CNTFAx15 Axokine, recombinant human variant of CNTF 
Cre site specific recombinase from phage P1 
CRH corticotrophin-releasing hormone 
CT-1 cordiotrophin-1 
CVO circumventricular organs 
d deci- 
  Abbreviations  
V 
Da Dalton 
DAPI 4',6-diamidino-2-phenylindole 
db/db mice homozygous for a point mutation in the leptin receptor gene  
ddH2O double destilled water 
DMH dorsomedial hypothalamic nucleus 
DMSO dimethylsulfoxide 
DNA desoxyribonucleic acid 
DNase desoxyribonuclease 
dNTP desoxyribonucleotide-triphosphate 
DTT 1,4-Dithio-DL-threitol 
e.g. exempli gratia 
ECL  enhanced chemiluminescence 
EDTA ethylendiamine tetraacetate 
eGFP enhanced green fluorescent protein 
ELISA enzyme-linked immunosorbent assay 
Erk extracellular signal-regulated kinase 
EtBr ethidium bromide 
EtOH ethanol 
floxed / lox loxP flanked 
FOXO1 forkhead-O transcription factor 1 
g gram 
G guanine 
G6Pase α glucose-6-phosphatase α  
Gab growth factor receptor binding protein associated binder 
GABA γ-aminobutyric acid 
GFP green fluorescent protein 
GLP-1 glucagon-like peptide 1 
GLUT-4 glucose transporter 4 
gp130 glycoprotein 130 
Grb2 growth factor receptor binding protein 2 
GTT glucose tolerance test 
Gusb glucuronidase beta 
h hour 
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H&E hematoxylin/eosin 
H2O2 hydrogen peroxide 
HCl hydrochloric acid 
HEPES N-2-hydroxyethylpiperazine-N’-2-ethansulfonic acid 
HFD high fat diet 
HGP hepatic glucose production 
HPA hypothalamic-pituitary-adrenal 
Hprt-1 hypoxanthine guanine phosphoribosyl transferase-1 
i.e. id est 
ip. intraperitoneal 
icv intracerebroventricular 
IGF-1 insulin-like growth factor-1 
IKK inhibitor of kappaB kinase 
IL-11 interleukin-11 
IL-6 interleukin-6 
IL-6R interleukin-6 receptor 
IR insulin receptor 
IRES internal ribosome entry site 
IRS insulin receptor substrate 
ITT insulin tolerance test 
JAK Janus kinase 
JNK c-Jun N-terminal kinase; 
k kilo 
kb kilobase pairs 
KCl potassium chloride 
kDa kilodalton 
KOH potassium hydroxide 
L liter 
LacZ gene encoding the enzyme ß-galactosidase 
Lepr leptin receptor 
LH lateral hypothalamic area 
LIF leukaemia inhibitory factor 
loxP recognition sequence for Cre (locus of x-ing over phage P1) 
  Abbreviations  
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m milli 
M molar 
MAPK mitogen-activated protein kinase 
MCR melanocortin receptor 
ME median eminence 
MEK MAPK/Erk Kinase 
MgCl2 magnesium chloride 
min minute 
mm milimeter 
mRNA messenger RNA 
MSH melanocyte-stimulating hormone 
n nano- 
n counts 
Na2HPO4 disodium hydrogen phosphate 
Na3O4V sodium orthovanadate 
NAc nucleus accumbens 
NaCl sodium chloride 
NaF sodium fluoride 
NaH2PO4 monosodium phosphate 
NaHCO3 sodium bicarbonate 
NaOH sodium hydroxide 
NIRKO neuron-restricted insulin receptor knockout mice 
NMR nuclear magnetic resonance 
NPY neuropeptide Y 
ob/ob mice homozygous for mutation in the leptin gene 
ObRb long isoform of the leptin receptor 
OD optical density 
OSM oncostatin M 
p pico- 
P phospho 
PAGE polyacrylamid gel electrophoresis 
PB phosphate buffer 
PBS phosphate buffered saline 
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PCR polymerase chain reaction 
PDK1 phosphoinositide-dependent protein kinase 1 
PFA paraformaldehyde 
PH pleckstrin homology 
PI3 kinase phosphatidylinositol 3 kinase 
PIP2 phosphatidylinositol (4,5) bisphosphate 
PIP3 phosphatidylinositol (3,4,5) trisphosphate 
POMC pro-opiomelanocortin 
PTB phosphotyrosine binding 
PTEN phosphatase and tensin homolog 
PVN paraventricular nucleus 
Raf proto-oncogene serine/threonine protein kinase 
Ras Ras small GTPase 
rhCNTF recombinant human CNTF 
RNA ribonucleic acid 
RNAi RNA interference 
RNase ribonuclease 
rpm rounds per minute 
RT room temperature 
RT-PCR real-time polymerase chain reaction 
s second 
s.c. subcutanous 
SCD-1 stearoyl-CoA desaturase-1 
SDS sodiumdodecylsulfate 
sec second 
SEM standard error of the mean 
SH src homology 
Shp-2 tyrosine phosphatase-2 
SIM-1 single minded homolog-1 
SN substantia nigra 
SOCS suppressor of cytokine signaling 
SOS son of sevenless 
ß-ga ß-galactosidase 
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ß-me ß-mercaptoethanol 
STAT signal transducer and activator of transcription 
TAE Tris-acetic acid-EDTA buffer 
TBP TATA-box binding protein 
TBS Tris buffered saline 
TE Tris-EDTA buffer 
Th tyrosine hydroxylase 
TNF-α tumor necrosis factor-α 
Tris 2-amino-2-(hydroxymethyl-)1,3-propandiole 
Trp tryptophan 
TWEEN polyoxethylene-sorbitan-monolaureate 
Tyr tyrosine 
U units 
UV ultraviolet 
V Volt 
v/v volume per volume 
VMH ventromedial nucleus of the hypothalamus 
VO2 volume of consumed oxygen 
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w/v weight per volume 
WAT white adipose tissue 
WHO World Health Organization 
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µ micro- 
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5. Introduction 
5.1. Obesity 
The prevalence of adult obesity and overweight among children has increased 
dramatically during the last decades. The World Health Organization (WHO) released 
that in 2005 approximately 1.6 billion adults were overweight and at least 400 million 
adults were obese. The WHO further projects that by 2015, approximately 2.3 billion 
adults will be overweight and more than 700 million will be obese. Overweight and 
obesity are defined as abnormal or excessive fat accumulation that may impair health 
(1), either leading to serious health consequences. Risk increases progressively as 
Body Mass Index (BMI) increases. Raised BMI is a major risk factor for chronic 
diseases including cardiovascular diseases (e.g. hypertension, heart diseases and 
stroke), diabetes mellitus type 2, sleep apnea and certain forms of cancer (2-4). 
The BMI is a simple index of weight-for-height that is commonly used in classifying 
overweight and obesity in adult populations and individuals. It is defined as the 
weight in kilograms divided by the square of the height in meters (kg/m2). The World 
Health Organization defines "overweight" as a BMI equal to or more than 25, and 
"obesity" as a BMI equal to or more than 30 (1).  
The fundamental cause of obesity and overweight is an energy imbalance between 
calories consumed on one hand, and calories expended on the other hand. The rapid 
increase in obese people results from a combination of genetic predisposition, 
enhanced availability of high-energy foods, and decreased physical activity in 
modern society. Lifestyle modifications and obesity drugs are the current efforts to 
diminish the growing epidemic, but so far, none of them is capable of ensuring a 
consistent and effective weight loss. As a result, new therapeutic approaches are 
required to treat the obesity epidemic.  
5.2. Energy homeostasis 
Obesity is the result of a long-term positive body energy balance namely, energy 
intake is greater than energy expenditure thus, excess calories are stored in the form 
of fat. On the other hand, negative energy balance leads to a decreased body mass. 
Thus, understanding the regulation of energy balance is crucial in the development of 
therapeutically strategies in the treatment of obesity (5, 6). 
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Energy homeostasis is primarily regulated by the central nervous system (CNS) (5). 
Neuronal systems involved in regulation of energy intake, energy expenditure and 
endogenous glucose production sense and integrate input from peripheral hormones 
and nutrient-related signals that transmit information about body energy stores and 
energy availability to the brain (5). Under circumstances of sufficient energy stores 
and energy availability, the CNS receives afferent signals that lead to the activation 
of anabolic pathways (inhibition of energy intake and endogenous glucose 
production, increase of energy expenditure and mobilization of fat stores). 
Conversely, in the state of low energy stores and food deficiency, catabolic 
responses are activated to promote positive energy balance (increased energy intake 
and glucose production, decreased energy expenditure). 
The afferent signals that are crucial for the regulation of energy homeostasis include 
the pancreatic β-cell hormone insulin as well as the adipocyte-derived hormone 
leptin.  
5.3. Insulin and the insulin receptor 
The anabolic peptide-hormone insulin is produced by the β-cells of the pancreatic 
islets of Langerhans. Insulin was discovered in 1921 by F. Banting, C. Best, J. 
Macleod and J. Collip., two years later, F. Banting and J. Macleod were awarded the 
Nobel Prize in Medicine for their discovery. In 1953, the primary sequence of insulin 
was decoded (7), followed by the crystal structure of the active form in 1966 (8). One 
year later, Steiner et al. identified the inactive precursor proinsulin, which is cleaved 
to insulin by different endopeptidases (9, 10). 
Insulin secretion from the pancreatic ß-cells is triggered predominantly in response to 
increased blood glucose levels (11, 12). Additionally, plasma insulin levels are also 
directly linked to the degree of body adiposity (13, 14). Insulin acts on peripheral 
tissues, particularly on muscle cells and adipocytes via translocation of the glucose 
transporter to remove the glucose from the blood and store it in form of glycogen (11, 
15). Moreover, insulin promotes anabolic processes such as stimulation of amino 
acid uptake and protein synthesis in muscle, glycogen synthesis in liver and muscle 
as well as lipogenesis in adipose tissue. Catabolic processes, on the other hand, 
such as glycogenolysis, lipolysis and proteolysis are inhibited by insulin (16). 
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In addition to its peripheral action, insulin circulates in proportion to the amount of 
body fat, crosses the blood-brain-barrier via a saturable transporter and acts on the 
CNS as an adiposity signal (17-20).  
 
The heterotetrameric insulin receptor is ubiquitously expressed and belongs to the 
family of ligand-activated receptor tyrosine kinases. Binding of insulin leads to 
autophosphorylation of the receptor on three intracellular tyrosine residues resulting 
in complete activation of the intrinsic tyrosine activity of the receptor. 
Receptor autophosphorylation results in recruitment and binding of intracellular 
proteins via their phosphotyrosine binding domains. Signaling molecules for the 
insulin receptor include the insulin receptor substrate (IRS) proteins 1-4 which are 
phosphorylated upon binding to the receptor, and thereby serve as a docking 
platform for other proteins, leading to the action of different downstream signaling 
pathways. 
There are two major pathways activated by the IRS proteins, the Ras/Raf Mitogen 
activated protein (MAP) kinase and the PI3 (phosphatidyl-inositol 3) kinase pathway 
(21). 
5.4. Leptin  
Leptin is a 16-kDa protein encoded by the ob (obese) gene with a structure similar to 
the 4-α-helical bundle cytokines (22). It is a circulating hormone secreted by the 
adipose tissue. First described in 1994 (23), leptin has proven to be a key metabolic 
protein that has actions throughout the body. Mice with mutations of the gene 
encoding leptin (ob/ob mice) as well as mice with mutations compromising the leptin 
receptor (db/db mice) become pathologically obese, infertile, hyperphagic, 
hypothermic, and diabetic (24). Analogous to insulin, plasma leptin levels are 
correlated directly with adipose tissue mass, and circulating leptin is transported into 
the brain via a saturable process (25, 26). A neuron-specific deletion of the leptin 
receptor bears analogy to the phenotype of the db/db mouse, indicating that the 
major role of leptin action to control energy homeostasis is accounted for by its 
signaling in the CNS (27). 
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5.4.1. The leptin receptor  
Several leptin receptor isoforms (LEPR-A to F) are encoded by a single leptin 
receptor gene, each containing an identical ligand binding domain, but varying by the 
presence or absence of a transmembrane domain or a complete cytosolic domain 
(28). Among the different isoforms, all arising from alternative mRNA splicing and/or 
proteolytic processing of the single Lepr gene (29, 30), only the long form of the 
leptin receptor (Ob-Rb) has been shown to activate intracellular signaling (31). Many 
effects of leptin on energy homeostasis are assignable to its action in the CNS, 
especially in the mediobasal hypothalamus, where the Ob-Rb is highest expressed 
(32). Ob-Rb is highly conserved among species and is essential for leptin action as 
observed in db/db mice, which actually lack only the Ob-Rb (31, 33). 
The leptin receptor is a single membrane-spanning receptor, belongs to the class I 
cytokine receptor family and shows the highest similarity to gp130 (glycoprotein 130) 
which is the common signal transducer for the interleukin 6 (IL-6) family of cytokines 
(34). Hormone binding to the Ob-Rb results in dimerization of the receptor and 
activation of the janus kinase/signal transducer and activator of transcription 
(JAK/STAT) signaling pathway (35). Activation of the constitutively associated JAK2 
leads to autophosphorylation on three different tyrosine residues of the receptor, 
whereas each phosphorylated tyrosine residue results in the activation of a different 
downstream signaling pathway (in figure 1 exemplified with STAT3) (36, 37). 
Phosphorylated STAT molecules dimerize and translocate to the nucleus to modulate 
transcription of multiple target genes via STAT-responsive elements (36). Here. 
STAT3 activates transcription of suppressor of cytokine signaling (SOCS) 3 (38), 
which is a negative regulator of proximal leptin signaling and directly binds to JAK2 in 
a leptin-dependent manner (39). SOCS3 attenuates leptin receptor signaling by 
inhibiting JAK-induced tyrosine phosphorylation of the receptor. 
Binding of leptin to the leptin receptor also mediates tyrosine phosphorylation of IRS 
and thereby activation of the PI3-kinase signaling pathway (40).  
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Figure 1.1: Leptin receptor signaling. 
Binding of leptin to Ob-Rb leads to activation of JAK2 and subsequently to JAK2-mediated 
phosphorylation of three different intracellular tyrosine residues of the receptor, resulting in the 
activation of different downstream signaling pathways. Phosphorylation and activation of STAT3 
molecules lead to a dimerization of STAT3. The dimers translocate to the nucleus and activate target 
genes including SOCS3, resulting in inhibition of leptin signaling via negative feedback loop. 
Additionally, phosphorylated JAK2 directly activates the IRS/PI3K and the Shp2/Erk (not illustrated) 
signaling pathway. Abbreviations: AKT, protein kinase B; IRS, insulin receptor substrate; JAK, janus 
kinase; Ob-Rb, long form of the leptin receptor; PI3K, phosphatidyl inositol 3 kinase; SOCS, 
suppressor of cytokine signaling; STAT, signal transducer and activator of transcript. 
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5.5. Central regulation of energy homeostasis 
5.5.1. The hypothalamus 
During the last decades, the research on central regulation of energy balance has 
focused on the hypothalamus. In vertebrates, the hypothalamus is a part of the 
diencephalon located below the thalamus, building up the floor of the third cerebral 
ventricle. Conventional histological techniques revealed nuclei as clusters of neurons 
within the hypothalamus. The mammalian hypothalamus consists of more than 40 
histologically distinct nuclei areas, which can often be further divided into subnuclei 
(41). Classical experiments utilizing lesions or electrical stimulation indicated that 
some of these nuclei act as discrete feeding and satiety centers (42). Here, the 
arcuate nucleus (ARC), the paraventricular nucleus (PVN), the ventromedial nucleus 
of the hypothalamus (VMH), the dorsomedial hypothalamic nucleus (DMH) and the 
lateral hypothalamus (LH) are the nuclei, which have been shown to be involved in 
regulation of feeding behavior (figure 1.4). Importantly, the hypothalamus has been 
shown to be involved in the regulation of many other body functions, e.g. the 
cardiovascular system, thermoregulatory- and stress responses, the regulation of 
drinking behavior and the autonomous nervous system (43). In addition, the 
hypothalamus plays an essential role in assuring the survival of the species by 
controlling the expression of sexual and maternal behaviors. Of fundamental 
importance to the function of the hypothalamus is its close connection with the 
pituitary gland and the now clearly established pathways for neural control of 
endocrine secretion patterns (44, 45). 
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Figure 1.4: Schematic anatomical structure of the hypothalamus. 
Diagram of the mediobasal hypothalamus, showing major hypothalamic regions implicated in 
regulation of food intake and energy expenditure. Abbreviations: 3V, third ventricle; ARC, arcuate 
nucleus, DMH, dorsomedial hypothalamic nucleus; LH, lateral hypothalamus; ME, median eminence; 
VMH, ventromedial nucleus of the hypothalamus; PVN, paraventricular nucleus. 
 
The ARC is located in the mediobasal hypothalamus flanking the base of the third 
cerebral ventricle right above the median eminence (figure 1.4), which is part of the 
inferior boundary of the hypothalamus. In the CNS, there are discrete areas localized 
in the ventricular walls, known as circumventricular organs (CVO) (46), in most of 
which the blood-brain-barrier (BBB) displays special characteristics. The median 
eminence is one of the brain windows which allows peptides and proteins secreted 
by the neural tissue to reach the blood stream, and enables neural cells to sense 
circulating plasma molecules, including insulin and leptin (47-49). The PVN is located 
at the dorsal end of the third ventricle and represents the hypothalamic part where 
numerous neuronal pathways involved in the regulation of energy balance converge, 
including projections from the ARC (41). Lesions of the PVN as well as the VMH, 
which is located directly above the ARC, results in severe hyperphagia and obesity 
(50, 51). The DMH is located dorsal of the VMH and was suggested to integrate 
information from the ARC, the PVN, and the LH (52). The LH, a very large and 
heterogenous area, is the most extensively interconnected area of the hypothalamus, 
thereby allowing it to modulate different functions, including cognitive and autonomic 
functions (43). 
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5.5.2. POMC, the melanocortin system and the regulation of energy 
homeostasis 
The melanocortin model is of great importance explaining the neuronal control of 
energy balance (5, 53). In this model, the ARC is considered a critical region for 
diverse reasons. Two functionally opposing neuronal populations have been studied 
in great detail: the orexigenic agouti related peptide / neuropeptide Y (AgRP/NPY)-
expressing and the anorexigenic pro-opiomelanocortin (POMC)-expressing neurons 
(figure 1.5). AgRP and NPY are anabolic neuropeptides that stimulate food intake 
and reduce energy expenditure (54-57), while the catabolic neuropeptide POMC 
suppresses food intake and increases energy expenditure (58).  
The orexigenic neuropeptide NPY, a 36 amino acid peptide, is one of the most 
abundant neurotransmitters (59, 60). NPY is widely expressed throughout the brain 
with highest concentration in the ARC (61). It is the most potent endogenous 
orexigenic signal, stimulates food intake, reduces energy expenditure (55, 56, 62), 
and centrally administered, NPY promotes positive energy balance resulting in 
obesity (56). 
The orexigenic neurotransmitter AgRP consists of 132-amino acids. It is co-
expressed with NPY in a distinct neuronal population of the ARC and functions as a 
melanocortin receptor 3/4 (MC3R/MC4R) antagonist. The adrenal gland is the only 
peripheral tissue with detectable AgRP expression (63). AgRP mRNA levels in the 
ARC are increased upon fasting (64), and reduction of hypothalamic AgRP mRNA 
results in increased metabolic rate and reduction of body weight without effecting 
food intake (65). Transgenic mice with ubiquitous overexpression of AgRP are obese 
(63). Central injection of AgRP increases food intake and is also capable of blocking 
intracerebroventricular (icv) α-melanocyte stimulating hormone (MSH) stimulated 
food intake (54, 66, 67). 
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Figure 1.5: Central regulation of energy homeostasis. 
The ARC contains both NPY/AgRP and POMC neurons, which are located close to the BBB, where 
they have preferential access to peripheral humoral signals such as the pancreas-derived hormone 
insulin and the adipocyte-secreted hormone leptin as well as nutritional signals such as glucose and 
free fatty acids. Both neuronal populations exert potent effects on energy balance mediated by their 
characteristic neuropeptides, which allow modulation of second order neurons. POMC neurons project 
predominantly to second order neurons in the PVN of the hypothalamus, where the POMC cleavage 
product α-MSH acts on MC4R to suppress food intake. AgRP serves as an inverse agonist for the 
MC4 receptor, thus counteracting the function of α-MSH. Abbreviations: α-MSH, α-melanocyte-
stimulating hormone; AgRP, agouti-related peptide; ARC, arcuate nucleus; MC4R, melanocortin 
receptor 4; NPY, neuropeptide Y; POMC, pro-opiomelanocortin; PVN, paraventricular nucleus. 
[Adapted from Schwartz MW, Porte D (68)] 
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While neonatal ablation of AgRP/NPY neurons has negligible impact on feeding, 
selective ablation of AgRP/NPY neurons in adult mice results in acute reduction of 
food intake (69, 70). 
The anorexigenic 32 kDa prohormone, POMC, is expressed in the pituitary gland, 
skin and hypothalamus (71-73). In a tissue-specific manner it is processed by 
prohormone convertases (PC) to different bioactive products including adreno-
corticotropin (ACTH), β-endorphin and α-, β-, and γ-MSH (74, 75). The energy status 
of the body is reflected by POMC mRNA levels, as POMC gene expression is 
reduced in negative energy balance and increased in positive energy balance (64, 
76, 77). The brain expresses two types of MCR, MC3R and MC4R (78, 79). Both 
receptor types are highly expressed in regions of the brain established to be 
important in the control of food intake and body weight (79, 80). MC4R knockout-
mice develop a maturity-onset obesity syndrome associated with increased food 
intake, hyperinsulinemia, hyperglycemia, and an increase in linear growth (81). 
Whereas ACTH is the predominant POMC product secreted by corticotroph cells in 
the pituitary, the principal identified agonist to MCRs expressed in the brain is α-MSH 
(82). Icv injection of α-MSH reduces food intake and increases energy expenditure 
(58), and mice lacking the POMC-derived peptides are obese (83). 
Both, AgRP/NPY and POMC neurons express insulin and leptin receptors and are 
targeted by the respective hormones (84, 85), and large body of evidence has 
revealed an important role for leptin-activated STAT3 signaling in the CNS and 
POMC/AgRP neurons specifically in control of energy homeostasis. Neuron-specific 
disruption of STAT3 results in hyperphagia, obesity, diabetes and infertility (86). 
Along this line, mice with disruption of STAT3 specifically in leptin receptor-
expressing neurons develop profound obesity (87). Lack of leptin receptor signaling 
or inactivation of STAT3 specifically in POMC neurons results in obesity and other 
elements of the metabolic syndrome in rodents (88, 89), indicating a role for STAT3 
signaling in POMC/AgRP neurons for maintaining normal energy homeostasis 
Deletion of STAT3 in AgRP/NPY neurons results in modest weight gain accompanied 
by mild hyperphagia (90). Interestingly, mice with a constitutive activation of STAT3 
signaling specifically in AgRP neurons are lean due to increased locomotor activity 
(185), assigning AgRP neurons and specifically STAT3 signaling a role in control of 
locomotor activity. Administration of leptin to the ARC stimulates expression of 
POMC (85, 91), and inhibits expression of AgRP and NPY (92, 93). Moreover, 
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administration of a MC4R antagonist attenuates the anorexigenic response to leptin 
(94). 
A major target site for leptin signaling is the ARC of the hypothalamus. Aside from 
the DMH and the VMH, the highest levels of Ob-Rb expression are found in the ARC 
(32). Both AgRP/NPY and POMC neurons within the ARC express the long form of 
the leptin receptor (95, 96) and are directly regulated by leptin. While the orexigenic 
AgRP/NPY-producing neurons are inhibited by leptin (97, 98), the anorexigenic 
POMC neurons are activated (97, 99). Thus, leptin stimulates the production and 
secretion of anorexigenic neuropeptides and reciprocally suppresses levels of 
orexigenic peptides. Consistently, ob/ob and db/db mice exhibit elevated levels of 
AgRP and NPY mRNA and reduced levels of POMC mRNA (76, 100, 101). 
Administration of leptin stimulates expression of POMC (85, 91) and inhibits 
expression of AgRP and NPY (92, 93). Moreover, administration of a MC4R 
antagonist attenuates the anorexigenic response of leptin (94). It has been shown 
that leptin increases the frequency of action potentials in POMC neurons by 
depolarization through a non-specific cation channel and reduced inhibition by local 
NPY neurons (99).  
Both AgRP/NPY and POMC neurons coexpress the insulin- and the leptin receptor 
(102, 103). Insulin signals to the ARC of the hypothalamus to inhibit orexigenic 
AgRP/NPY neurons and to stimulate anorexigenic POMC neurons (5, 102, 104, 105). 
Central administration of insulin results in increased POMC and decreased NPY 
expression, without affecting the expression of AgRP (92) Recently, it was shown 
that insulin signaling in AgRP neurons is required for insulin’s ability to suppress 
hepatic glucose production (106). 
Besides the ability of the CNS to integrate information about the body energy status 
derived from hormones like insulin and leptin, the hypothalamus can also respond 
directly to circulating concentrations of nutrients, in particular of glucose and free fatty 
acids. Central administration of glucose decreases blood glucose levels (107) and 
central administration of oleic acid inhibits food intake by inhibiting NPY gene 
expression (108).  
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5.6. The hypothalamic-pituitary-adrenal axis 
The Hypothalamic-Pituitary-Adrenal (HPA) axis is complex system of direct 
influences and feedback interactions among the PVN of the hypothalamus, the 
anterior lobe of the pituitary gland and the adrenal glands. It is a major part of the 
neuroendocrine system that controls reactions to stress, and regulates multiple body 
processes including the immune system, energy storage and expenditure and 
sexuality. Corticotrophin-releasing hormone (CRH) synthesized and released by the 
PVN is the principal regulator of anterior pituitary corticotroph ACTH secretion (109). 
Interleukin-2, interferons, and the gp130 cytokine family participate in ACTH 
regulation and mediate the immuno-neuroendocrine interface. Pituitary corticotroph 
POMC expression is regulated by ;CRH as well as the gp130 receptor cytokine family 
(110, 111). Gp130 cytokines activate the HPA axis even in the absence of CRH (112-
114). ACTH stimulates adrenal glucocorticoid release that in turn acts as a negative 
feedback on CRH and ACTH production.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: The HPA-axis 
During inflammation and stressors that induce systemic cytokine production, CRH production by the 
PVN of the hypothalamus leads to POMC expression and ACTH release in the pituitary gland. ACTH 
stimulates adrenal corticosterone production, leading to a negative feedback cycle [red arrows = 
negative regulation, green arrows = positive regulation]. Abbreviations: CRH; corticotrophin releasing 
hormone, ACTH; adrenocorticotropin. 
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5.7. Gp130 and cytokine signaling 
5.7.1. Cytokines 
Pleiotropy and redundancy in biological activities are characteristic features of most 
cytokines (115, 116). As soluble mediators acting at low concentrations (nano- to 
pico-molar) they play an important role in the communication between cells. Unlike 
hormones, cytokines are not stored in glands, but are rapidly synthesized and 
secreted by different cells predominantly after stimulation. They exert their biological 
functions through specific cell surface receptors on their target cells. Cytokines have 
been classified on the basis of molecular cloning and structural analysis (117, 118) 
Furthermore, molecular and structural analysis of the related receptors accounted for 
the classification of different cytokine families (119). 
5.7.2. The interleukin-6-type cytokine family 
Originally, IL-6 was identified as a B cell differentiation factor, inducing B cell 
maturation to antibody forming plasma cells (120). However, cloning of IL-6 revealed 
that IL-6 is a typical multifunctional cytokine that affects not only immune response 
but also the hematopoietic, endocrine, hepatic and even the neural system (116, 
121-124). IL-6 is closely related to a group of other cytokines, such as interleukin-11 
(IL-11), oncostatin M (OSM), leukaemia inhibitory factor (LIF), cardiotrophin (CT)-1 
and ciliary neurotrophic factor (CNTF), all of them exhibit a similar helical structure 
characterized by four antiparallel α-helices (119).  
The so called “IL-6-type cytokines” reveal not only a redundancy in biological 
activities but furthermore, all members of this family signal via receptors with 
common structural features, comprising the class I cytokine receptor family (125-
130).  
5.7.3. Class I cytokine receptors and gP130 
The receptors involved in IL-6-type cytokine signaling are type I membrane proteins 
(extracellular N-terminus, one transmembrane domain), with the exception of the 
CNTF receptor (CNTFR), which is linked to the plasma membrane by a glycosyl-
phosphatidyl inositol anchor (128). All class I cytokine receptors are defined by the 
presence of at least one cytokine-binding molecule consisting of two fibronectin–
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type-III-like domains of which the N-terminal domain contains a set of four conserved 
cysteine residues and the C-terminal domain a WSXWS (tryptophan-serine-X-
tryptophan-serine) motif (119). 
Molecular cloning of the IL-6 receptor (IL-6R) revealed that the IL-6R complex 
consists of two components. First, an IL-6 binding molecule termed IL-6Rα, a 
relatively short cytoplasmatic region containing only 82 amino acids, and second the 
signal transducing 130-kDa membrane gp130 which has no IL-6-binding capacity by 
itself but plays a critical role in the formation of high-affinity IL-6-binding sites (131, 
132). Other receptors for IL-11, OSM, LIF, CT-1 and CNTF were molecularly cloned 
and revealed a structure similar to the IL-6Rα (figure 1.2) (119, 133).  
The functional redundancy of the IL-6 family of cytokines can be explained by the 
molecular biology of the cytokine receptor system. All class-I-receptor complexes 
share gp130 as a common signal transducer, but each cytokine requires a private 
ligand-specific receptor. IL-6, IL-11, and CNTF first bind specifically to their α 
receptor subunits (IL-6Rα, IL-11Rα, and CNTFRα, respectively) before the signaling 
receptor subunits are engaged. Also, an α-subunit for CT-1 has been postulated, but 
since it has not been cloned yet, its existence is uncertain (134). The complexes 
between IL-6 and IL-6Rα, and between IL-11 and IL-11Rα signal through gp130 
homodimers; the complex of CNTF and CNTFRα signals through a heterodimer of 
gp130 and the LIFR, another signal-transducing receptor subunit. The cytokines LIF 
and OSM do not require binding to non-signaling α receptors; they engage the 
signaling receptor subunits directly. LIF uses a heterodimer of gp130 and LIFR to 
transduce signals. Human OSM has the exceptional capability to recruit two different 
receptor complexes it forms both, LIFR/gp130 and OSM-specific receptor component 
(OSMR)/gp130 heterodimers (135) (figure 1.2). 
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Figure 1.2: Class I cytokine receptors. 
Schematic models of the receptors for IL-6, IL-11, OSM, LIF, CT-1 and CNTF. IL-6 and IL-11 first bind 
specifically to their α-receptor subunits, IL-6Rα and IL-11Rα, only the complex of cytokine and α-
receptor efficiently recruits gp130 for homodimerization. OSM utilizes two different heterodimers, 
either LIF/gp130 or OSM/gp130. LIF binds to the LIFR, which then becomes heterodimerized with 
gp130. The LIFR/gp130 heterodimer is further utilized for CT-1 binding and signaling. Like IL-6 and IL-
11, CNTF first binds to its α-receptor subunit, CNTFRα, which is structural closely related to the 
extracellular region of IL-6R and is anchored to the membrane via a glycosyl-phosphatidyl-inositol 
linkage. Abbreviations: CNTF, ciliary neurotrophic factor; CT-1, corticotrophin-1; gp130, glycoprotein 
130; IL-6, interleukin-6; IL-11, interleukin-11; LIF, leukaemia inhibitory factor; OSM, oncostatin M; R, 
receptor. 
5.7.4. Cytokine signaling 
IL-6 type cytokines utilize tyrosine kinases of the JAK family and transcription factors 
of the STAT family as major mediators of signal transduction. Additionally, the MAPK 
cascade or a signaling cascade involving PI3K/AKT can be activated by IL-6 type 
cytokines (135, 136). 
The first event in IL-6-type cytokine signaling is the ligand-induced homo-or hetero-
dimerization of signal-transducing receptor subunits resulting in activation of the 
associated JAKs, which phosphorylate themselves and the receptor. These 
phosphorylation sites serve as docking sites for the SH2 domain containing STATs, 
such as STAT3, and for SH2-containing proteins and adaptors that link the receptor 
to MAPK or PI3K/AKT. 
Receptor-bound STATs, phosphorylated by JAKs, dimerize and translocate into the 
nucleus to regulate target gene transcription. Members of the SOCS protein family 
reduce receptor signaling via homologous or heterologous feedback regulation 
(analogous to leptin signaling, see figure 1.1).  
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In the event of the MAPK pathway, the activated receptor binds to the Grb2-SOS 
complex via its docking protein SHP2. The SOS protein then activates Ras, which in 
turn phosphorylates a series of MAP kinases (Raf, MEK, MAPK). MAPK enters the 
nucleus and subsequently phosphorylates and activates transcription factors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Cytokine signaling. 
The figure illustrates the principles of cytokine signaling exemplified with IL-6. IL-6 binding to IL-6Rα 
leads to activation of JAK and subsequently to JAK-mediated phosphorylation of intracellular tyrosine 
residues of the receptor, resulting in the activation of different downstream signaling pathways. 
Phosphorylation and activation of STAT 3 molecules lead to a dimerization of STAT3 molecules. The 
dimers translocate to the nucleus and activate target genes. Additionally, phosphorylated JAK leads to 
the activation of the MAPK cascade and can also trigger the PI3K signaling pathway. Abbreviations: 
AKT, protein kinase B; gp130, glycoprotein 130; Grb2, growth factor receptor-bound protein 2; IL-6, 
interleukin-6; MAPK, mitogen-activated protein kinase; MEK, MAPK/Erk kinase; PI3K, phosphatidyl 
inositol 3 kinase; R, receptor; Raf, proto-oncogene serine/threonine protein kinase; Ras, small 
GTPase; SOS, son of sevenless; SHP2, SH2-containing phosphatase 2; TF, transcription factor. 
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5.8. CNTF 
In 1979, CNTF, a 24 kDa protein, was first identified and partially purified as a factor 
which promoted survival of chick ciliary ganglion neurons (137). Subsequently, it was 
shown that CNTF is also present in large amounts in sciatic nerves of adult rats and 
rabbits, which led to its final purification and cloning (138, 139). Further studies 
revealed that CNTF is expressed in glial cells within the central and peripheral 
nervous systems. It stimulates gene expression, cell survival or differentiation in a 
variety of neuronal cell types such as sensory, sympathetic, ciliary and motor 
neurons. In addition, non-neuronal cells, such as oligodendrocytes, microglial cells, 
liver cells, and skeletal muscle cells, respond to exogenously administered CNTF, 
both in vitro and in vivo (140).  
CNTF mediates its effects by binding to the CNTF-receptor-α (CNTFRα) (141). As 
described above, ligand binding leads to heterodimerization of gp130 and the LIFR, 
activating the JAK/STAT signaling pathway (128). Interestingly, the IL-6R is able to 
serve as an α-receptor for CNTF (142), both, CNTF and IL-6 possess a specific 
combination of three binding epitopes, which leads to different ligand-receptor 
interactions (143). CNTFRα expression is most abundant in the CNS; however, it is 
expressed in numerous peripheral tissues including skeletal muscle (128, 141).  
CNTF was first considered as an antiobesogenic pharmaceutical, when amyotrophic 
lateral sclerosis (ALS) patients were treated with recombinant human CNTF 
(rhCNTF), in attempt to slow disease progression. The endpoint of the study, the 
slope of decline of isometric muscle strength in treated versus placebo patients, 
showed no statistically significant difference between rHCNTF and placebo-treated 
patients, remarkably, the side effects of rhCNTF included anorexia and weight loss 
(144). Since this study, numerous rodent studies have further substantiated the 
antiobesogenic properties of CNTF and its second-generation analog, Axokine 
(Axokine) (145-150). 
In peripheral tissues such as skeletal muscle, CNTF upregulates AMPK activation, 
thereby increasing fatty acid oxidation (151). Furthermore, CNTF acts to decrease 
steatosis in the liver and lipid build up in skeletal muscle (147, 152). The promotion of 
fatty acid oxidation and lowered lipid accumulation in liver and skeletal muscle 
decrease the activation of serine threonine kinases (JNK and IKK) and the 
transcription of stearoyl-CoA desaturase (SCD)-1 in liver to improve lipid-induced 
insulin resistance. 
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5.8.1. CNTF and the CNS 
In situ hybridization with cRNA probes for murine Ob-Rb and CNTFRα, revealed that 
both receptors are co-localized in the arcuate nucleus and the paraventricular nuclei, 
hypothalamic regions involved in the regulation of energy balance (148, 153). CNTF 
treatment of ob/ob mice was found to reduce adiposity, hyperphagia, and 
hyperinsulinemia associated with leptin deficiency. Unlike leptin, CNTF also reduced 
obesity-related phenotypes in db/db mice, and in mice with diet-induced obesity, 
which are partially resistant to the actions of leptin (148). Furthermore, recombinant 
CNTF was able to reverse the obese phenotype in leptin resistant rodent models and 
to prevent rebound weight gain after the end of treatment (150). Pharmacological 
experiments indicated that CNTF, similar to leptin is capable of suppressing NPY 
mRNA levels, and NPY application counteracts the weight reducing effects of CNTF 
(154). However, CNTF and leptin initiate differential patterns of gene expression in 
the ARC and CNTF possesses inflammatory properties distinct from leptin (155, 
156), indicating diverging mechanisms of action and potentially differential target 
sites of both hormones. 
5.8.2. Axokine 
Axokine (CNTFAx15), a second-generation neurotrophic factor that is related to CNTF, 
was developed by Regeneron Pharmaceuticals for the potential treatment of obesity 
and associated complications such as diabetes mellitus type 2. Axokine is the 
designation for recombinant human CNTF with the following modifications: 
substitutions of alanine for cystein at position 17 and arginine for glutamine at 
position 63, and deletion of the 15 C-terminal amino acids. Axokine is four to five 
times more potent than the CNTF parent molecule as measured by in vitro neuronal 
survival assays and in vivo studies and has improved stability properties over CNTF 
(157-160). 
  Introduction  
19 
5.9. Objectives 
Obesity and type 2 diabetes mellitus are intimately connected diseases and their 
incidences are steadily increasing worldwide. Therefore, there is an urgent need for 
the development of therapeutically approaches to treat the obesity epidemic. CNTF 
exerts anorectic effects by overcoming leptin resistance via activation of 
hypothalamic neurons. However, the exact site of CNTF action in the hypothalamus 
has not been identified yet. Using Cre-loxP-mediated recombination in vivo, the 
common gp130 signal-transducing subunit, which is required for functional CNTF 
signaling, was ablated selectively in POMC-expressing neurons (gp130∆POMC mice). 
Characterization of gp130∆POMC mice elucidated the physiological role of gp130 
signaling in POMC neurons, particularly on the regulation of energy homeostasis and 
neuropeptide expression. Additionally, the effect of exogenous CNTF on food intake 
and body weight was analyzed by central CNTF administration. 
 
 
. 
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6. Material and Methods 
6.1. Chemicals  
Table 1: Chemicals 
 
Chemicals Supplier 
Acrylamide (Rotiphorese Gel 30®) Roth, Karlsruhe, Germany 
Actrapid (Insulin) Novo Nordisk, Bagsværd, Denmark 
Agarose Invitrogen, Karlsruhe, Germany 
Aprotinin Sigma-Aldrich, Seelze, Germany 
APS Sigma-Aldrich, Seelze, Germany 
Avertin (2,2,2-tribromoethanol) Sigma-Aldrich, Seelze, Germany 
Benzamidin Sigma-Aldrich, Seelze, Germany 
Bromphenol Blue Merck, Darmstadt, Germany 
CNTF R&D Systems,  
DEPC Applichem, Darmstadt, Germany 
Dimethylsulfoxide (DMSO)                           Merck, Darmstadt, Germany 
Dithiothreitol DTT Applichem, Darmstadt, Germany 
Enhanced Chemiluminscence (ECL) Kit Perbio Science, Bonn, Germany 
Ethanol Applichem, Darmstadt, Germany 
Ethidium Bromide Sigma-Aldrich, Seelze, Germany 
Ethylendiamine tetraacetate (EDTA) Applichem, Darmstadt, Germany 
Forene® (Isoflurane) Abbott, Wiesbaden, Germany 
Glucose, 20% DeltaSelect, Pfullingen, Germany 
Glycerine Merck, Darmstadt, Germany 
Glycin Applichem, Darmstadt, Germany 
Hepes Applichem, Darmstadt, Germany 
Isopropanol Roth, Karlsruhe, Germany 
Leptin Sigma-Aldrich, Seelze, Germany 
LPS Sigma-Aldrich, Seelze, Germany 
Methanol Roth, Karlsruhe, Germany 
NaF Applichem, Darmstadt, Germany 
Paraformaldehyde (PFA) Applichem, Darmstadt, Germany 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Seelze, Germany 
Phosphate buffered NaCl (PBS) Gibco BRL, Eggenstein, Germany 
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Proteinase K Roche, Mannheim, Germany 
Sodium Azide Merck, Darmstadt, Germany 
Sodium Chloride, 0,9% DeltaSelect, Pfullingen, Germany 
Sodium Dodecyl Sulfate (SDS) Applichem, Darmstadt, Germany 
Sodium fluoride Merck, Darmstadt, Germany 
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany 
Sucrose  
Trishydroxymethylaminomethane (Tris) Applichem, Darmstadt, Germany 
Triton X-100  Applichem, Darmstadt, Germany 
Tween 20 Applichem, Darmstadt, Germany 
Western Blocking Reagent Roche, Karlsruhe, Germany 
β-Mercaptoethanol (β-ME) Applichem, Darmstadt, Germany 
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6.2. Animals 
All animal procedures were conducted in compliance with protocols approved by 
local government authorities (Bezirksregierung Köln) and were in accordance with 
National Institutes of Health guidelines. Mice were housed in groups of 3-5 at 22-
24°C in a 12 : 12 h light/dark cycle with lights on at 6 a.m. Animals were either fed 
regular chow food (Teklad Global Rodent # T.2018.R12; Harlan, Germany) 
containing 53.5% of carbohydrates, 18.5% of protein, and 5.5% of fat (12% of 
calories from fat) or a high fat containing diet (HFD) (# C1057; Altromin, Germany) 
containing 32.7%, 20% and 35.5% of carbohydrates, protein and fat (59.36% of 
calories from fat), respectively. Water was available ad libitum and food was only 
withdrawn if required for an experiment. Body weight was measured once a week. 
Genomic DNA was isolated from tail tips, genotyping was performed by PCR. At the 
end of the study period, the animals were killed in isoflurane anaesthesia. 
6.2.1. Generation of PomcCre-gp130lox/lox mice 
PomcCre mice (88) were mated with gp130lox/lox mice (161), and a breeding colony 
was maintained by mating gp130lox/lox with PomcCre-gp130lox/lox mice. Gp130lox mice 
had been backcrossed for at least 5 generations on a C57BL/6 background, and 
PomcCre mice (initially established on a FVB background) had been backcrossed for 
two generations on a C57BL/6 before intercrossing them with gp130lox mice. Only 
animals from the same mixed background strain generation were compared to each 
other. PomcCre mice were genotyped by PCR as previously described (88), gp130lox 
mice were genotyped by PCR with primers flanking the first loxP site (5gp130, 
3gp130). Germline deletion was excluded using a third primer, binding ~300 bp 
downstream the second loxP site. For visualization of Cre-mediated recombination, 
mice were crossed with either the indicator strain RosaArte1 (LacZ reporter) (162) or 
the Z/EG reporter strain (163). 
6.2.2. Restraint stress and LPS treatment 
Mice were adapted to gentle handling for approximately 8 weeks prior to the 
experiment. To determine basal serum corticosterone and IL-6 levels, blood was 
drawn from the tail vein during the first 3 hours (h) of the light phase. The following 
  
 Material and Methods  
23 
day, mice were subjected to 1h of restraint stress at the same time of the light phase. 
Restraint stress was achieved by enclosing the animals in a plastic tube with a 
diameter of 3 cm and openings at both ends for tail and nose. The length of the tube 
was adjusted to the size of the animal to ensure complete immobilization. At the end 
of the experiment, blood samples were again drawn from the tail vein. 
Seven days later the animals were injected intraperitoneal (ip.) with 0.9%NaCl during 
the first 3 h of the light phase, blood was collected from the tail vein 1 h after 
injection. After five days of recovery, each mouse received an ip. injection of 300µg 
LPS (L 2630 Sigma, Germany), 1 h after injection blood samples were taken. Two 
days after LPS injection the animals were sacrificed in isoflurane anaesthesia. 
6.2.3. Glucose and insulin tolerance tests 
Glucose tolerance tests were performed with 16h fasted animals. After determination 
of fasted blood glucose levels, each animal received an ip. injection of 20%Glucose 
(10ml/kg). Blood Glucose levels were detected after 15, 30, 60 and 120 minutes 
(min). 
Insulin tolerance tests were performed with mice fed ad libitum. After determination of 
basal blood glucose levels, each animal obtained an ip. injection of insulin, 0,75U/kg 
(Actrapid®). Additional blood glucose values were collected 15, 30 and 60 min after 
insulin injection. 
6.2.4. Indirect calorimetry and food intake 
All measurements were performed with a Comprehensive Laboratory Animal 
Monitoring System (CLAMS, Oxymax Windows 3.0.3; Columbus Instruments, OH, 
USA). Mice were placed at room temperature (22°-24°C) in 3.0-liter chambers of the 
CLAMS open circuit calorimetry. Settling time was set at 150 seconds (sec) and 
measuring time at 60 sec with room air as reference. Food and water were ad libitum 
provided in the appropriate devices. Mice were allowed to acclimatize in the 
chambers for 24 h. Parameters of indirect calorimetry were measured for at least the 
following 72 h. Food intake was measured continuously in the CLAMS during the 
experiment. Presented data are average values obtained in these recordings. 
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6.2.5. Icv cannula implantation  
12 week old mice were anesthetized by ip. injection of Avertin® (240mg/kg) and 
placed in a stereotactic device. A sterile osmotic pump connector cannula (Bilany 
Consultants GmbH, Germany) was implanted into the lateral brain ventricle (0.2 mm 
posterior and 1.0 mm lateral relative to bregma and 2.3 mm below the surface of the 
skull). The support plate of the catheter was attached to the skull with superglue. The 
catheter was prefilled with sodium chloride (NaCl) and connected to a sealed micro-
renathane catheter (MRE-025; Braintree Scientific, Inc., MA, USA).  
6.2.6. Icv injections 
After 5 days of recovery, the sealed micro-renathane catheter was removed. Over 1 
min, 5µl NaCl was injected, to avoid a backflow, the catheter was sealed with hot 
clamps. The following day, 4µl recombinant Rat CNTF, 0.25 mg/ml (557-NT/CF, R&D 
Systems) were injected followed by 1µl of NaCl to assure complete drug absorption 
to the lateral ventricle. Injections were performed in isoflurane anaesthesia 1h before 
the onset of the dark cycle. 
Food intake and body weight were measured 4h and 24 h (female mice) and 6h/24h 
(male mice) after the injection. Correct position of the icv cannula was verified in 
each animal by injection of methyl blue after sacrificing the mice. Only data from 
animals successfully injected with NaCl and CNTF was analyzed  
6.2.7. Axokine treatment 
Axokine was purchased from Regeneron Pharmaceuticals, Terrytown, NY. Placebo 
was freshly prepared every 3-4 days containing 10mM sodium phosphate, 0, 05% 
Tween®80, 3% PEG 3350, and 20% sucrose in ddH2O.  
After weaning, mice were fed with high fat containing diet. At the age of 10 weeks, 
only mice with sufficient weight gain were accustomed to daily subcutaneous (sc.) 
injection 1 hour before onset of the dark period with placebo for 5 days. The body 
weight of all groups at the beginning of the experiment averaged out between 33 and 
34 g. Subsequent treatment with either Placebo or Axokine (0.1µg/kg/day) for 7 days 
was followed by 16 days of continuous monitoring.  
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6.2.8. Molecular biology 
Standard methods of molecular biology were performed according to Sambrook and 
Russell, unless stated otherwise. 
6.2.9. Isolation of genomic DNA 
Mouse tail biopsies were incubated 1 hour (h) in lysis buffer (100 mM Tris-HCl (pH 
8.5), 5 mM EDTA, 0.2% (w/v) SDS, 0.2 M NaCl and 500 mg/ml proteinase K) in a 
thermomixer (Eppendorf, Hamburg, Germany) at 56°C. DNA was then precipitated 
from the solution by adding an equivalent of isopropanol. After centrifugation, the 
DNA pellet was dried at 60°C for 10 min and resuspended in doubly distilled water 
(ddH2O). 
6.2.10. Polymerase chain reaction (PCR) 
The PCR method was used to genotype mice for the presence of floxed alleles or 
transgenes with customized primers listed in table 3. Reactions were performed in a 
Thermocycler iCycler PCR machine (Bio-Rad, München, Germany) or in a Peltier 
Thermal Cycler PTC-200 (MJ Research, Waltham, USA). All amplifications were 
performed in a total reaction volume of 25µl, containing a minimum of 50ng template 
DNA, 25pmol of each primer, 25µM dNTP Mix, 10 x RedTaq reaction buffer and 1 
unit of RedTaq DNA Polymerase. PomcCre PCR program started with 5 min 
denaturation at 95°C, followed by 35 cycles consisting of denaturation at 94°C for 60 
sec, annealing at 55°C for 30 sec and elongation at 72°C for 90 sec and a final 
elongation step at 72°C for 7 min. gp130-deletion/gp130-flox PCR program started 
with 4 min denaturation at 94°C, followed by 35 cycles consisting of denaturation at 
94°C for 30 sec, annealing 54°C for 30 sec and elongation at 72°C for 45 sec and a 
final elongation step at 72°C for 7 min. 
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Table 2: Oligonucleotides for genotyping 
 
Primer Sequence (5’-3’) 
PomcCre AA03 GAG ATA TCT TTA ACC CTG ATC 
PomcCre N57R CAC ATA AGC TGC ATC GTT AAG 
PomcCre N16R TGG CTC AAT GTC CTT CCT GG 
5gp130 GGT GGC TGA TTC ACC TGC A 
3gp130 TAC GCT GGG CAG CGT CCT 
gp130∆ GAA ACA CTC ATG CTG AAA CC 
 
All primers were purchased from Eurogentec, Cologne, Germany. PCR-amplified 
DNA fragments were applied to 1% - 3% (w/v) agarose gels (1 x TAE, 0.5mg/ml 
ethidium bromide) and electrophoresed at 120V. 
6.2.11. Hypothalamic neuropeptide expression 
Neuropeptide mRNA was analyzed using quantitative real-time (RT)-PCR. RNA was 
isolated from hypothalamic blocks respectively pituitaries using the Qiagen RNeasy 
Kit (Qiagen, Germany). The RNA was reversely transcribed with EuroScript Reverse 
Transcriptase (Eurogentec, Belgium) and amplified using TaqManR Universal PCR-
Master Mix, NO AmpErase UNG with TaqManR Assay on demand kits (Applied 
Biosystems, CA, USA) with the exception of the detection of POMC mRNA. 
Customized primers were used with POMC sense 5’-
GACACGTGGAAGATGCCGAG-3’; anti-sense, 5’-CAGCGAGAGGTCGAGTTTGC-
3’; probe sequence, 5’-FAM-CAACCTGCTGGCTTGCATCCGG-TAMRA-3’. Relative 
expression of neuropeptide mRNA was determined using standard curves based on 
hypothalamic copy (c) DNA and samples were adjusted for total RNA content by 
TATA-box binding protein (TBP) RNA quantitative PCR. Calculations were performed 
by a comparative method (2-ddCT). Quantitative PCR was performed on an ABI-
PRISM 7700 Sequence Detector (Applied Biosystems, Germany). Assays were 
linear over 4 orders of magnitude. 
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6.3. Analytical procedures 
6.3.1. ELISA and RIA 
Blood glucose levels were determined from whole venous blood using an automatic 
glucose monitor (GlucoMen® GlycÓ; A. Menarini Diagnostics, Italy). Insulin, leptin 
and Il-6 levels in serum were measured by ELISA using mouse standards according 
to manufacturer’s guidelines (Mouse Leptin ELISA, Mouse/Rat Insulin ELISA; 
CrystalChem, IL, USA / BD OptEIATMMouse Il-6 ELISA Kit; BD Biosciences, 
Pharmingen CA). Corticosterone serum levels were determined by RIA using mouse 
standards according to manufacturer’s guidelines (ImmuChemTMDouble Antibody 
Corticosterone 125I RIA Kit; INC Biomedicals, Inc., CA, USA). 
6.3.2. Protein extraction 
Snap-frozen tissues were thawed and homogenized in lysis buffer (50mM HEPES 
(pH 7.4), 1% Triton X-100, 0.1M Sodiumfluoride, 10mM EDTA, 50mM 
Sodiumchloride, 10mM Sodiumorthovanadate, 0,1% SDS, 10µg/ml Aprotinin, 2mM 
Benzamidine, 2mM PMSF) using a polytron homogenizer (IKA Werke, Staufen, 
Germany). Particulate matter was removed by centrifugation for 1h at 4°C. The 
supernatant was transferred to a fresh vial and protein concentrations were 
determined using a Bradford assay. Protein extracts were diluted to 1mg/ml with lysis 
buffer and 4 x SDS sample buffer (125mM Tris-HCl (pH 6.8), 5% SDS, 43.5% 
glycerine, 100mM DTT, and 0.02% bromophenol blue), incubated at 95°C over 5min 
and stored at -80°C. 
6.3.3. Western blot analysis  
Frozen protein extracts were thawed at 95°C for 5min, then separated on 8-10% 
(v/v) SDS polyacrylamide gels and blotted onto PVDF membranes (Bio-Rad, 
München, Germany). Membranes were then incubated with 1% blocking reagent 
(Roche, Mannheim, Germany) for 1h at RT or over night at 4°C. Subsequently, 
primary antibodies (gp130 (# sc-656, Santa Cruz Biotechnology, Inc., CA, USA) and 
Pten (# MS-1250-P; NeoMarkers, CA, USA) as loading control) diluted in 0.5% 
blocking solution were applied for 1h at RT or over night at 4°C. PVDF membranes 
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were then washed twice for 10min with 1 x TBS/Tween and incubated twice for 
10min with 0.5% blocking solution. After 1h incubation at RT with the respective 
secondary antibodies, membranes were washed 4 times for 5min with 1 x 
TBS/Tween, incubated for 1min in Pierce ECL Western Blotting Substrate (Perbio 
Science, Bonn, Germany), sealed in a plastic bag and exposed to 
chemiluminescence film (Amersham, Braunschweig, Germany) at -80°C. Films were 
developed in an automatic developer. 
 
6.4. Immunohistochemistry 
6.4.1. Intraveneous stimulation and tissue preparation 
Control and PomcCre-GP130lox/lox mice were mated with RosaArte1 reporter mice 
(162). At the age of 10 weeks, ad libitum fed mice received one intravenous injection 
of 5g recombinant rat CNTF, 20µg Leptin (L-3772, Sigma) or NaCl into the tail vein. 
30min after injection the mice were perfused with 0.9% NaCl followed by 4% 
paraformaldehyde (in PBS), the brains were extracted, kept in 4% PFA over night at 
4°C and stored in 20% sucrose at 4°C.  
For one series, we performed double-labeling of p-Stat3 and β-galactosidase 
(indicating POMC-expressing neurons). Therefore, free-floating tissue sections were 
extensively washed to remove cryoprotectant, then pre-treated with 100% methanol 
pre-cooled to 20°C and incubated for 20min at room temperature in 0.3% glycine in 
PBS for 10min. and 0.03% SDS in PBS for 10min including PBS washes during the 
steps. After that, sections were blocked for 1h (3% normal donkey serum in 
PBS/0.4% Triton X-100/ 0.2% sodium-azide) followed by incubation of the primary 
antibodies rabbit anti-p-Stat3 (1:3000 diluted in blocking solution; Cell Signalling, MA, 
USA) and goat anti-β -galactosidase (1:3000 diluted in blocking solution; Biogenesis, 
UK) for 48h at 4°C. Sections were extensively washed in PBS, incubated protected 
from light for 2h at room temperature in anti-rabbit-Alexa488 (Molecular Probes; OR, 
USA) for labelling of p-Stat3 antibodies and biotinylated anti-goat antibody (West 
Grove, PA, USA) for detection of β-galactosidase antibodies (both at 1:200 dilution in 
blocking solution without sodium-azide). The biotinylated anti-goat antibody was then 
further labelled with Alexa568-conjugated streptavidin (1:200; Molecular Probes) for 
1h in the dark at room temperature. Sections were mounted onto gelatine coated 
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slides, dried and coverslipped using mounting media (ProLong® Gold; Molecular 
Probes). Fluorescence signals were detected under a fluorescent microscope (BX-
51; Olympus, NY, USA) and representative pictures of the ARC were taken with a 
digital colour camera (DP70; Olympus). 
6.4.2. Tissue preparation without stimulation 
Animals were perfused with PBS followed by 4%PFA for 5min. Brain and pituitary 
were separated and post-fixed in 4%PFA at 4°C over night. The following day the 
tissue was transferred to 20% Sucrose/PBS, after 6h the brains/pituitaries were 
washed in PBS, dabbed and frozen in tissue freezing medium. After cutting into 
25µm sections the sections were stored in PBS-azide at 4°C until further use. 
Day1: Brain sections were rinsed with PBS 2x for 10min, washed in freshly prepared 
0.3%H2O2 for 30min and rinsed in PBS 3x for 10min. After blocking in PBT-azide 
w/3% donkey serum for 1h, the sections were transferred into primary antibody (Anti-
GFP rabbit serum, Molecular Probes #A-6455, Invitrogen, Germany) and incubated 
on a shaker ~50rpm over night (prim. antibody, 1:10000, + 3% donkey serum + PBT-
Azide). 
Day2: Sections were washed with PBS 5x for 10min and transferred into secondary 
antibody (anti-rabbit IgG, # 711-065-125, Jackson ImmunoResearch, PA, USA) on a 
shaker ~50rpm for 1h (2nd antibody, 1:500,+ 3% donkey serum + PBT, no azide). 
After incubation, the sections were rinsed with PBS, 3x for 10min, incubated in ABC 
(Avidin Biotin Complex-Vectastain Elite) for 1h, again washed with PBS, 2x for 10min 
and incubated in 0,04% DAB and 0,01% H2O2 ~4 min. Subsequently the sections 
were rinsed with PBS 2x for 10min, dried, mounted onto gelatine-coated slides and 
covered with glycerine. 
Pituitary was stained with the same antibodies, using Tyramide Signal Amplification 
kit (TSA™ Fluorescence Systems, Perkin Elmer, MA, USA).  
6.4.3. POMC cell counting 
For quantification of β-galactosidase positive POMC cells, tissues were processed as 
described for pStat3/β-galactosidase double immunohistochemistry and stained for 
β-galactosidase. Pictures from every 4th section throughout the ARC (generally 12-13 
adjacent sections bregma -1.1mm to -2.7mm) were taken and all sections were 
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allocated in a rostral to caudal manner to visualize the distribution of POMC 
neurones throughout the ARC. Using Adobe Photoshop software β-galactosidase 
positive neurones were counted and marked digitally to prevent multiple counts. Cell 
counts were performed on 3 animals per group and cell numbers represents every 4th 
section throughout the ARC. 
The percentage of double positive cells compared to the total amount of β-
galactosidase positive POMC cells after CNTF stimulation was also determined by 
counting. 
6.4.4. Immunostainig for c-Fos 
As described above, catheter implanted animals received 1h before onset of the dark 
phase an injection of either NaCl or recombinant rat CNTF. 6h later, the mice were 
anesthetised by Avertin® and perfused with NaCl followed by Somogyi-Takagi-
Fixative. The brains were dissected, kept in glutaraldehyde-free fixative at 4°C for at 
least 2h and were stored in 0.1M phosphate buffer at 4°C until further preparation. 
Immunostaining for c-Fos was carried out as previously described (164). 
6.5. Statistical methods 
Data was analyzed for statistical significance using a two-tailed unpaired student’s T-
Test.  
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7. Results 
7.1. POMC-restricted inactivation of gp130. 
To investigate the role of gp130 signaling in POMC neurons, mice carrying the loxP-
flanked (flox) gp130 allele (161) were crossed with mice expressing the Cre 
recombinase under control of the Pomc promoter (figure 3.1) (88).  
 
 
Figure 3.1: POMC-specific inactivation of the gp130 gene. 
(a) Map of the loxP-flanked gp130 gene exon 16. Cre mediated recombination of this allele (gp130lox) 
leads to removal of the transmembrane exon (exon 16) and a resulting frame shift, thereby leading to 
generation of gp130∆. (b) Map of the PomcCre transgene. Mice expressing Cre recombinase (Cre) 
under the control of the Pomc promoter were generated by engineering a POMC bacterial artificial 
chromosome. The Cre translational initiation site (ATG) was inserted to the POMC ATG and deleted 
the first 30bp of the Pomc gene. (c) Breeding strategy for gp130∆ mice: Mice, homozygous for the loxP 
flanked exon 16 of the gp130 allele (gp130 lox/lox) were crossed with gp130lox/lox mice expressing the 
Cre protein under the control of the Pomc promoter.  
 
 
  
 Results  
 
32 
ßgeo eGFPpCAGGS 3xpA pA
Cre-mediated recombination was visualized by crossing PomcCre mice to a reporter 
mouse strain (Z/EG) which expresses the enhanced green fluorescent protein 
(eGFP) after Cre-mediated deletion of a lox-P flanked lacZ gene (figure 3.2a) (163). 
These mice showed a pattern of eGFP immunoreactivity in the ARC of the 
hypothalamus similar to POMC (figure 3.2b). 
 
 
a) 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: eGFP immunoreactivity pattern in the ARC of gp130∆POMC mice. 
(a) Map of the Z/EG expression construct. The Z/EG transgene consists of the strong pCAGGS 
(chicken ß actin promoter with upstream CMV enhancer) promoter, directing expression of a loxP-
flanked ßgeo (lacZ/neomycin-resistance) fusion gene and three SV40 polyadenylation sequences 
(3xpA). Followed by the coding sequence of the enhanced green fluorescence protein (eGFP) and a 
rabbit ß globin polyadenylation sequence (pA). In this configuration, ßgeo is expressed before Cre 
excision, and eGFP is expressed after Cre excision. 
(b) Mice carrying the Z/EG reporter construct were mated with gp130∆POMC and immunohistochemistry 
for eGFP was performed in double transgenic mice (scale bar 100µm). 
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To confirm the specificity of gp130 inactivation, Western blot analyses were 
performed. Consistent with restricted inactivation in POMC neurons, Western blot 
analysis revealed no alterations in overall brain and hypothalamic gp130 protein 
expression (figure 3.3). Accordingly, gp130 expression in peripheral tissues remained 
unchanged in gp130∆POMC mice (figure 3.3). 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Western blot analysis of gp130 expression. 
Western Blot analysis of gp130 and pten (loading control) in brain, hypothalamus (HT), liver and white 
adipose tissue (WAT) in wildtype (WT) and gp130∆POMC (KO) mice. 
 
7.2. Abolished CNTF-stimulated STAT3 tyrosine phosphorylation in 
POMC cells of gp130∆POMC mice. 
To determine the effects of a POMC-restricted gp130 deficiency on CNTF`s ability to 
induce STAT3 phosphorylation, wildtype and gp130∆POMC mice were mated to a 
second reporter mouse strain. In this strain transcription of the ß-galactosidase gene 
(LacZ) under control of the ubiquitously expressed Rosa26 promotor is prevented by 
a floxed hygromycin resistance gene (LacZ reporter mice), thus leading to ß-
galactosidase (ß-gal) expression only in cells expressing the Cre recombinase (figure 
3.4a) (162). In wildtype reporter mice, injection of recombinant CNTF intravenously 
resulted in profound activation of STAT3 phosphorylation in both POMC- and non-
POMC- expressing neurons of the ARC (figure 3.4b). In contrast, in gp130∆POMC 
reporter mice, CNTF treatment resulted in tyrosine phosphorylation of STAT3 in non-
POMC-cells, but it failed to activate STAT3 phosphorylation in POMC neurons (figure 
3.4b and c).  
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To determine the specificity of gp130 ablation in POMC neurons for gp130-
dependent cytokine signaling, both wildtype and gp130∆POMC mice were treated with 
intravenous leptin injection. 
Leptin treatment evoked a profound stimulation of STAT3 tyrosine phosphorylation in 
both POMC- and non-POMC- cells of wildtype and gp130∆POMC mice (figure 3.4b). 
These data indicate, that POMC-restricted inactivation of gp130 selectively inhibits 
signaling via gp130-coupled cytokine receptors such as the CNTF receptor, without 
abolishing the gp130 independent cytokine receptor signaling such as that mediated 
by the leptin receptor 
 
a) 
 
b) 
 
 
 
 
 
 
 
 
c) 
        
 
 
 
 
 
Figure 3.4: Specific ablation of gp130 signaling in POMC neurons. 
(a) Map of the LacZ transgene for Cre-mediated expression from the Rosa26 locus. pGK-hyg: 
hygromycin resistance gene driven by the pGK (phosphoglycerate kinase) promoter. (b) Double 
immunohistochemistry for p-STAT3 (green) and ß-gal (red) in POMC neurons of wildtype (gp130+/+) 
and gp130∆POMC (gp130-/-) mice 30 minutes after intravenous stimulation with NaCl, leptin or 
recombinant CNTF. (ME = median eminence; 3V = third ventricle) (c) Quantification of p-STAT3-
positive POMC cells after CNTF stimulation in wildtype (WT) and gp130∆POMC (KO) mice (mean ± SEM 
of three animals in each group) (P < 0.001).  
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7.3. Unaltered POMC cell numbers and stress response in gp130∆POMC 
mice. 
Gp130 has been demonstrated to play a critical role in neurogenesis (165). 
Therefore, it was determined whether lack in functional gp130 signaling alters the 
number or distribution of hypothalamic POMC cells.  
This analysis revealed equal numbers and distribution of POMC cells in both wildtype 
and gp130∆POMC mice (figure 3.5). These data indicate that disrupted gp130 signaling 
did not affect neurogenesis and cell survival of POMC cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Unaltered POMC cell numbers and distribution. 
Quantitative and spatial analysis of POMC cells in wildtype (open bars) and gp130∆POMC (filled bars) 
mice (n = 3 of each genotype).  
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Consistent with the expression pattern of endogenously expressed POMC, the only 
non-hypothalamic site of recombination detectable in PomcCre-transgenic mice was 
the pituitary (figure 3.6a).  
 
 
 
 
 
 
 
 
Figure 3.6: Pituitary POMC expression. 
(a) Immunohistochemistry for eGFP performed in the pituitary of LacZ reporter mice. (b) Relative 
expression of POMC mRNA in pituitaries of wildtype (WT) and gp130∆POMC (KO) mice (n = 7-8). 
 
Because cytokines that signal through gp130-dependent receptors such as 
leukaemia inhibiting factor (LIF) and IL-6 have been demonstrated to regulate 
adrenocorticotropin expression and release in cultured pituitary cells (166), we next 
characterized the functional stress response of gp130∆POMC mice. 
POMC mRNA expression in the pituitary of wildtype and gp130∆POMC mice was 
comparable (figure 3.6b). To determine the stress response in wildtype and 
gp130∆POMC mice, we used two paradigms activating the corticotropic response via 
distinct mechanisms, i.e. restraint stress and LPS injection. Both stimuli dramatically 
increased plasma corticosterone concentrations to a comparable extent in wildtype 
and gp130∆POMC mice (figure 3.7a). As expected, LPS injection resulted in a profound 
increase of circulating IL-6 concentrations (figure 3.7b)(167). This increase was 
indistinguishable between wildtype and gp130∆POMC mice.  
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Figure 3.7: Unaltered stress response in gp130∆POMCmice. 
(a) Plasma corticosterone concentrations: basal and 1h after NaCl injection, restraint stress, or LPS 
treatment in wildtype (open bars; n = 6-10) and gp130∆POMC (filled bars; n= 7-12) mice. (b) IL-6 plasma 
concentrations: basal and 1h after NaCl injection, restraint stress, or LPS treatment in wildtype (open 
bars; n = 6) and gp130∆POMC (filled bars; n= 7) mice. 
Taken together, these data implicate that inactivation of gp130 signaling in POMC 
cells of the hypothalamus and pituitary does not impair responses to restraint and 
LPS-induced stress in these animals. 
7.4. Normal energy and glucose homeostasis in gp130∆POMC mice. 
To determine the importance of endogenous gp130-dependent signaling in POMC 
cells on the regulation of energy homeostasis, the body weight of wildtype and 
gp130∆POMC mice from weaning until 6 month of age was monitored. This analysis 
revealed no change in body weight in the presence of POMC-restricted gp130 
deficiency both under standard and high fat diets (figure 3.9a). White adipose tissue 
mass and circulating plasma leptin concentrations were indistinguishable between 
wildtype and gp130∆POMC mice (figure 3.8b and c). In wildtype and gp130∆POMC mice, 
there was an increase in adipose tissue mass and plasma leptin concentrations upon 
exposure to high–fat diet (figure 3.8b and c). Food intake and basal metabolic rate 
were also indistinguishable between wildtype and gp130∆POMC mice (figure 3.8d and 
e). Furthermore, the expression of anorexigenic neuropeptides such as POMC and 
cocaine- and amphetamine-related transcript (CART) was unaltered in wildtype and 
gp130∆POMC mice (figure 3.8f). Moreover, body length was indistinguishable between 
wildtype and gp130∆POMC mice, a further indication of intact function of the 
melanocortin pathway in the absence of gp130 signaling in POMC neurons (figure 
3.8g).  
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Figure 3.8: Normal energy homeostasis in gp130∆POMC mice. 
(a) Body-weight curve of wildtype (open squares and open triangles) and gp130∆POMC (filled squares 
and filled triangles) mice on standard diet (SD) (squares; n = 12-18) and high fat-diet (HFD) (triangles; 
n = 12-31). (b) Epigonadal fat pads were dissected and weighed. Data represent the mean ± SEM of 
14-31 mice in each group. (c) Serum leptin levels of wildtype (n = 10-16) and gp130∆POMC (n = 10-16) 
mice on SD and HFD at the age of 24 weeks. (d) Daily food intake of wildtype (n = 6) and gp130∆POMC 
(n = 9) mice at the age of 11 weeks. (e) Basal metabolic rate (BMR) of wildtype (n = 6) and 
gp130∆POMC (n =9) mice at the age of 11 weeks. (f) Relative expression of POMC and CART on 
wildtype (open bars; n = 7-8)) and gp130∆POMC (filled bars; n = 6-7) mice. (g) Body length of wildtype (n 
= 13) and gp130∆POMC (n = 13) mice. 
 
Consistent with unaltered energy homeostasis in gp130∆POMC mice, these animals 
exhibit normal glucose metabolism as assessed by glucose tolerance tests, insulin 
tolerance tests, and blood glucose and plasma insulin concentrations (figure 3.9a, c, 
e and f). Exposure to high fat diet resulted in impaired glucose tolerance, increased 
blood glucose concentrations, and elevated plasma insulin concentrations as an 
indirect measure of insulin resistance in a similar manner in wildtype and gp130∆POMC 
mice (figure 3.9b and d-f).  
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Taken together, these data indicate that gp130 signaling in POMC neurons is 
dispensable for normal wildtype of body weight, food intake, energy expenditure, and 
glucose metabolism. 
 
     a)     b) 
 
 
 
 
 
 
     c)        d) 
 
 
 
 
 
 
     e)         f) 
 
 
 
 
 
 
Figure 3.9: Unaltered glucose metabolism in gp130∆POMC mice. 
(a) GTT of wildtype (□, n=10) and gp130∆POMC (■, n=10) mice at the age of 17 weeks on standard diet. 
(b) GTT of wildtype (□, n=13) and gp130∆POMC (■, n=17) mice at the age of 17 weeks on high fat diet. 
(c) ITT of wildtype (□, n=10) and gp130∆POMC (■, n=10) mice at the age of 22 weeks on standard diet. 
(d) ITT of wildtype (□n=13) and gp130∆POMC (■, n=19) mice at the age of 22 weeks on high fat diet.  
(e) Basal blood glucose levels of wildtype (white bars, n=20) and gp130∆POMC (black bars, n=30-32) 
mice on standard diet (SD) and on high fat diet (HFD) at the age of 17-22 weeks.  
(f) Serum insulin levels of wildtype (white bars) and gp130∆POMC (black bars) mice on standard diet 
and on high fat diet at the age of 20 weeks (n = 10-13 for each group and genotype) 
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7.5. Blunted anorectic response to centrally injected CNTF in 
gp130∆POMC mice. 
To analyze the effect of exogenous CNTF on food intake, cannulae were implanted 
into the lateral ventricle of wildtype and gp130∆POMC mice and after a few days of 
recovery, central injection of NaCl or CNTF was conducted.  
Notably, female wildtype mice exhibited a highly significant reduction in food intake, 
4h (-83%) and 24h (-43%) after central CNTF injection, compared to NaCl injection, 
respectively (figure 3.10a). Consequently, a delayed but highly significant reduction 
of body weight followed. 4h after CNTF injection, wildtype females had lost 4,6% of 
body weight, after 24h the loss added up to 10,2%, compared to weight loss after 
NaCl stimulation, respectively (figure 3.10b). Female gp130∆POMC mice (figure 3.10b) 
also exhibited a significant reduction in food intake 4h after CNTF injection, but in 
contrast to the more than 80% reduction in food intake in wildtype mice, food intake 
was only reduced by 35% in gp130∆POMC mice. Strikingly, 24h after CNTF injection, 
no significant difference in food intake after NaCl- and CNTF- injection was 
detectable in female gp130∆POMC mice (figure 3.10a). Again as a consequence of 
reduction of food intake, gp130∆POMC females exhibited a weight loss of 2,8% 4h after 
CNTF injection. 24h after CNTF injection they hat lost 4,4% compared to weight loss 
after NaCl injection (figure 3.10b). Although body weight was significantly reduced in 
female gp130∆POMC mice, the effect of centrally administered CNTF was more potent 
in wildtype mice.  
Strikingly, however, when male wildtype and gp130∆POMC mice were acutely treated 
with CNTF: 6-h food intake after single central injection was significantly reduced by 
60% in wildtype animals, whereas male gp130∆POMC mice failed to exhibit a significant 
reduction of food intake (figure 3.10c). Body weight significantly decreased by 4% in 
CNTF-treated wildtypes, whereas it remained unchanged in male gp130∆POMC  mice 
(figure 3.10d). Taken together, CNTF rapidly and severely impaired food intake over 
a 24-h period in wildtype females and males. Notably, milder effects were observed 
in female gp130∆POMC mice, whereas in male gp130∆POMC mice the acute anorectic 
effect of POMC- mediated CNTF signaling was almost completely blunted. 
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Figure 3.10: Blunted anorectic response to centrally injected CNTF in gp130∆POMC mice.  
Central injection of either 0.9% NaCl or 1µg of recombinant rat CNTF into the lateral ventricle of 13- to 
15-week-old mice. (a) Food intake of female wildtype (open bars) and gp130∆POMC (filled bars) mice, 
0.9% NaCl-treated, 4 and 24h after icv CNTF injection (mean ± SEM of 9-10 animals in each group) (P 
< 0.05, P < 0.01). (b) Body weight of female wildtype (open bars) and gp130∆POMC (filled bars) mice, 
0.9% NaCl-treated, 4 and 24h after icv. CNTF injection (mean ± SEM of 9-10 animals in each group) 
(P < 0.05). (c) Food intake of male wildtype (open bars) and gp130∆POMC (filled bars) mice, 0.9% NaCl-
treated, 6h after icv CNTF injection (mean ± SEM of 6-16 animals in each group) (P < 0.01). (d) Body 
weight of male wildtype (open bars) and gp130∆POMC (filled bars) mice, 0.9% NaCl-treated, 6h after icv 
CNTF injection (mean ± SEM of 6-16 animals in each group) (∗: p ≤ 0,05; ∗∗:p ≤ 0,01; ∗∗∗:p ≤ 0.001). 
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7.6. CNTF fails to induce c-Fos immunoreactivity in the PVN of 
gp130∆POMC mice.  
The PVN of the hypothalamus is a major site of action of POMC efferents in the 
regulation of feeding (168). Therefore, the activation of PVN neurons in response to 
acute CNTF treatment in wildtype and gp130∆POMC mice was analyzed. In wildtype 
animals, CNTF evoked a strong induction of c-Fos immunoreactivity in the PVN 
(figure 3.11). Strikingly, however, CNTF treatment completely failed to enhance c-
Fos immunoreactivity in the PVN of male gp130∆POMC mice (figure 3.11).  
 
  a)         b)     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Gp130∆POMC mice are resistant to the acute anorectic effect of centrally injected 
CNTF.  
(a) c-Fos expression in the PVN of wildtype and gp130∆POMC mice 6h after icv injection of 0.9% NaCl 
or CNTF. (b) Quantification of c-Fos positive cells in the PVN of wildtype and gp130∆POMC mice 6h 
after icv. injection of 0.9% NaCl or CNTF 
 
Thus, CNTF application acutely and strongly activates neurons in the PVN that are 
characterized as important mediators of energy homeostasis regulation (168). The 
absence of PVN neuronal activation in response to CNTF application in gp130∆POMC 
mice clearly indicates that PVN activation critically depends on functional CNTF 
signaling in POMC neurons. 
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7.7. Reduced weight loss in gp130∆POMC mice after chronic Axokine 
treatment. 
Chronic treatment with the human recombinant variant of CNTF, Axokine, reduces 
body weight, increases metabolic rate and improves diabetic parameters (146, 147). 
With the objection of extending the prior short-term experiments, a seven-day period 
of daily Axokine injections in wildtype and gp130∆POMC mice was performed, followed 
by 16 days of monitoring. During the injection period, additional groups of wildtype 
and gp130∆POMC mice were substituted with placebo.  
As expected, the placebo group remained unaffected and showed a normal weight 
gain after the injection period (figure 3.12).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12:. The effect of chronic Axokine treatment is impaired in gp130∆POMC mice  
Relative body weight changes of wildtype (open symbols) and gp130∆POMC mice (filled symbols).Seven 
days of daily Axokine injections are followed by a 16 day follow-up care. Body weight was measured 
daily, and is shown as the percentage difference of the initial body weight.  
Placebo injected mice (squares) maintained their original body weight during the treatment and 
exhibited a constant weight gain afterwards. Axokine treated mice (0.1µg/kg/day, triangles) revealed a 
drastic weight loss during the treatment, however, gp130∆POMC mice lost significantly less weight 
compared to wildtype mice. Analog to placebo treated mice, in both, wildtype and gp130∆POMC mice, a 
subsequent weight gain followed. The body weight difference between placebo and Axokine treated 
mice remained constant during the follow-up care period. (□: placebo treated wildtype mice, n=16; ■: 
placebo treated gp130∆POMC mice, n=13; ∆: Axokine treated wildtype mice, n=16; ▲: Axokine treated 
gp130∆POMC mice, n=15; ∗: p ≤ 0,05; ∗∗:p ≤ 0,01). 
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In contrast, Axokine treated wildtype mice sustained a clear weight loss up to 13% 
during the injection period (figure 3.12). The Axokine dependent weight loss of 
gp130∆POMC mice was significantly attenuated compared to Axokine-treated wildtype 
mice. Gp130∆POMC mice only lost up to 10 % body mass. The weight difference 
between Axokine-treated wildtype and gp130∆POMC mice persisted during the 16 day 
follow-up care period but the relative body weight regain was comparable to the 
placebo treated wildtype groups. 
In summary, the anorectic effect of chronic Axokine treatment is significantly 
diminished in animals with POMC-specific ablation of gp130 signaling.  
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8. Discussion 
8.1. CNTF: a potential therapeutic tool for the treatment of obesity. 
Obesity and type 2 diabetes are the most prevalent metabolic diseases in the 
western world (1). Many disorders directly correlate with obesity, including glucose 
intolerance, dyslipidemia and insulin resistance. Several pharmacological substances 
are in use to treat these disorders, unfortunately the current therapeutic strategies 
exhibit disadvantages and limitations, therefore the aim of research is the 
development of an omnipotent drug. The discovery of leptin and the leptin receptor 
presented a completely new idea in the therapeutic control of obesity, because it 
established a link between a circulating molecule and modification of central feeding 
behavior. After years of research, it became evident, that obesity is characterized by 
a dysfunctional leptin signaling leading to insulin resistance (169). Hence, the idea of 
leptin as an obesity therapeutic received less consideration for years and the focus 
changed to subjects more promising. However, recent studies demonstrate profound 
anti-obesity effects of combining leptin with other substances, e.g. rimonabant, a 
cannabinoid type 1 receptor antagonist (170), amylin a hormone co-secreted with 
insulin (171), or the combination of amylin and cholecystokinin a peptide involved in 
the control of appetite (172). 
Formerly, in 1979, CNTF was identified as a factor which promoted survival of chick 
ciliary ganglion neurons (173, 174). In the 1990s, CNTF was considered as a 
promising treatment for ALS and several studies were conducted, first in animal 
models (175, 176) and subsequent in clinical trials (144, 177). The observation that 
anorexia and weight loss are side effects of CNTF treatment, lead to further rodent 
studies, investigating the anti-obesogenic properties of CNTF and recombinant 
human CNTF (Axokine). CNTF exerts anorectic effects by engaging CNS sites 
distinct from leptin (155) and has provided an attractive therapeutic tool for the 
treatment of obesity (146, 148, 150, 178). 
It`s clinical use so far has been limited due to the development of neutralizing 
antibodies in patients treated with the recombinant variant of CNTF, although 
ongoing research aims to overcome this immunity (146). 
Despite intense research over the years, the exact site of CNTF action in mediating 
its anorectic effect has yet not been identified. Expression of the CNTF receptor is 
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most abundant in the CNS (141), furthermore it is present in numerous peripheral 
tissues (128).  
POMC neurons are an important primary site of leptin action in the brain and critical 
for energy homeostasis (76, 179, 180). Considering previous studies describing co-
localization of the CNTFRα and the Ob-Rb in brain regions involved in the regulation 
of energy balance (85, 148), the question was raised whether POMC neurons 
contribute to the anorectic effects of CNTF. The CNTF signaling cascade depends on 
gp130 signaling molecules (136), accordingly, neuron-specific deletion of gp130 
represents a functional approach for exploring CNTF`s mode of action. 
8.2. POMC-specific deletion of gp130. 
In order to explore the role of POMC cells in mediating CNTF`s biological effects on 
feeding, a POMC cell-specific deletion of gp130 (gp130∆POMC) was generated. 
Therefore, mice carrying the loxP-flanked gp130 allele (161) were crossed with mice 
expressing the Cre recombinase under control of the Pomc promoter (88). 
In the present study, Western Blot analysis showed no alterations in overall brain, 
hypothalamic and peripheral tissue expression of gp130. However, 
immunohistochemistry revealed an abolished STAT3 tyrosine phosphorylation in 
POMC cells of gp130∆POMC mice, providing a functional confirmation of the gp130 
signaling disruption in these neurons. Nevertheless, in gp130∆POMC mice the pattern 
of STAT3 phosphorylation within the hypothalamus differed between leptin and 
CNTF stimulated mice. This is consistent with previous studies reporting a robust 
phospho (p)-STAT3 staining in the ventromedial part of the ARC after CNTF 
stimulation, whereas leptin-stimulated STAT3 phosphorylation was more prominent 
in the lateral ARC and the ventromedial hypothalamus (160). However, even though 
this points to a differential expression of CNTF and leptin receptors within different 
neuronal populations of the ARC, the functional results of this study reveal that CNTF 
signaling plays a critical role in POMC cells. Thus, both CNTF and leptin target at 
least this cell type. 
Gp130 has been demonstrated to play a critical role in neurogenesis (181). In 
addition, Shimazaki et al. suggest, that CNTF/LIFR/gp130-mediated signaling 
supports the maintenance of forebrain neuronal stem cells (182). Therefore, in the 
present study arcuate POMC cell number in gp130∆POMC mice was assessed. 
Quantitative and spatial analysis revealed an unaltered number of POMC cells in the 
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arcuate nucleus, indicating that disrupted gp130 signaling in gp130∆POMC mice does 
not affect neurogenesis and cell survival of POMC neurons.  
Despite from the CNS, POMC is expressed in pituitary corticotrophs, for this reason 
POMC expression in gp130∆POMC pituitary cells was visualized by 
immunohistochemistry, and a normal expression pattern was visible. Additionally, 
mRNA expression was unaltered in gp130∆POMC mice. Given that pituitary 
corticotroph POMC gene expression is amongst others regulated by members of the 
gp130 cytokine family (183) and gp130 cytokines activate the HPA axis even in the 
absence of CRH (112), systemic stress tests were conducted to evaluate the effects 
of the POMC specific gp130 knockout on the HPA axis. Neither endotoxic nor 
restraint stress revealed a significant difference between wildtype and gp130∆POMC 
mice, implicating that POMC cell dependent gp130 signaling in the pituitary is 
negligible in respect of the systemic stress response. 
Since leptin receptor signaling in POMC neurons is required for normal body weight 
homeostasis (88), and administration of CNTF activates leptin-like pathways and 
results in reduced feeding, body weight and insulin levels in leptin-resistant mouse 
models (150) it is likely, that the lack of gp130 mediated CNTF signaling in POMC 
neurons leads to an imbalance of energy regulation. However, extensive phenotyping 
exhibited that the POMC-specific deficiency of gp130 has no impact on body weight, 
food intake, energy expenditure and glucose metabolism, both in mice fed with 
standard diet and mice on high fat diet, indicating that neither endogenous CNTF nor 
any other endogenous gp130 cytokine do influence energy homeostasis via POMC 
neurons.  
In summary, gp130∆POMC mice represent a functional POMC specific gp130 knockout 
without effecting vital functions or energy metabolism.  
8.3. Impaired anorectic response to acute central CNTF treatment and 
reduced body weight loss during chronic systemic Axokine treatment 
in gp130∆POMC mice. 
The anorectic and weight reducing effects of CNTF previously described by multiple 
studies result from pharmacological doses of CNTF (146, 150, 154, 155, 160, 178, 
184). The majority of these studies performed subcutaneous or intraperitoneal 
injections of Axokine, a recombinant variant of CNTF (150, 152, 178, 185). In these 
experiments, Axokine administration activates gp130 signaling in both, peripheral 
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organs and the CNS (150, 185). Considering the neuronal specificity of the gp130 
knockout, central application of CNTF represents a more specific and direct 
approach. Therefore, in the present study the effect of acute central CNTF treatment 
was investigated in wildtype and gp130∆POMC mice. As expected, wildtype mice 
exhibited a highly significant reduction in food intake, subsequently followed by a 
profound decrease in body weight. Strikingly, pharmacological doses of centrally 
injected CNTF, resulted in a blunted anorectic response in male gp130∆POMC mice. 
There were no significant changes in food intake and body weight after central 
administration of CNTF, indicating that POMC-mediated gp130 signaling plays a 
critical role in mediating CNTF`s acute anorectic effect. Surprisingly, female 
gp130∆POMC mice revealed a significant reduction in food intake 4h after CNTF 
injection. Notably, this effect was less evident compared to wildtype mice and 24h 
after CNTF injection, no significant difference was detectable in CNTF treated 
animals compared to NaCl injection. Body weight reduction occurred delayed but 
according to food intake reduction, therefore, female gp130∆POMC mice exhibited a 
significant reduction in body weight over the 24-h period but it is worth mentioning, 
that the body weight reducing effect in wildtype mice was more pronounced 
compared to gp130∆POMC mice.  
Even though the underlying mechanism for this sexually dimorphic phenotype 
remains unsolved, our data are in line with other studies using genetic mouse models 
of obesity (84, 186, 187). Other studies, analyzing the effect of centrally administered 
agents such as insulin and leptin on energy homeostasis (188) also report different 
phenotypes and pharmacological responses depending on gender. 
A recent study reported, that estrogen-induced decrease in body weight was 
dependent on STAT3 activation in the brain (189), since chronic estrogen 
administration in a mouse model of brain STAT3 knockout had no effect on body 
weight. In contrast, estrogen centrally injected into the third ventricle of rats 
significantly reduced food intake 4-14h after treatment (189).  
Furthermore, the authors demonstrated an increased number of c-Fos expressing 
POMC neurons in the ARC upon estrogen treatment in rats, indicating that estrogen 
might be able to elevate POMC tone in a leptin like manner (189, 190). Bearing in 
mind that estrogen exerts multiple effects on the hypothalamus including influencing 
energy balance (191), one could speculate, that estrogen action in some extent 
bypasses the absent POMC-mediated CNTF signaling in female gp130∆POMC mice. 
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Thus, CNTF signaling in arcuate cell populations other than POMC expressing cells 
remained unaffected in female gp130∆POMC mice and, central stimulation with 
pharmacological doses of CNTF triggers an increase in STAT3 expression. This, in 
turn might lead to an estrogen-mediated reduction in food intake, thereby inducing 
the observed weight loss. Given that male mice have lower levels of estrogen, the 
consequences of disrupted POMC-mediated CNTF signaling might be more 
pronounced. Unfortunately, the interactions between estrogen and hypothalamic 
cytokine signaling remain to be investigated. Therefore, further studies are necessary 
to elucidate the sexually dimorphic phenotypes in energy homeostasis 
The PVN of the hypothalamus is a major site of action of POMC efferents in the 
regulation of feeding (168). Stereotaxic microinjection of either α-MSH or AgRP into 
the PVN alters food intake and energy expenditure (192, 193). Furthermore, animals 
with PVN lesions exhibit distinct hyperphagia (194). Therefore, in the present study 
the activation of PVN neurons in response to acute CNTF treatment was analyzed. 
Strikingly, however, CNTF application completely failed to enhance c-Fos 
immunoreactivity in the PVN of gp130∆POMC mice. According to this, the present study 
revealed that CNTF treatment acutely and strongly activates neurons in the PVN that 
are characterized as key mediators of energy homeostasis regulation (168). Thus, 
the current experiments define a functional neuronal circuit in which CNTF signaling 
in POMC neurons is essential for CNTF’s acute inhibitory effect on food intake and 
the activation of PVN neurons. These results again are in line with the fact that CNTF 
engages similar intracellular signaling mechanisms to those activated by leptin 
stimulation (150, 155).  
Remarkably, one unique feature of CNTF is protection from weight rebound upon 
termination of treatment (150, 178). Long-term observations in diet-induced obese 
mice revealed a persisting effect on body weight even after termination of Axokine 
treatment (178). Furthermore, they report that Axokine alters energy homeostasis 
and improves metabolic control in diet-induced obese mice (178). Therefore, it is 
crucial to determine whether this long-term protection also depends on functional 
gp130 signaling in POMC neurons. Consequently, Axokine treatment was performed 
over a 7-dy period in diet-obese wildtype and gp130∆POMC mice in anology to 
previous studies (147, 150, 160, 178). As expected, subcutaneously applied Axokine 
significantly reduced body weight in wildtype animals. In contrast, the body weight 
reducing effect of Axokine was impaired in gp130∆POMC mice. While Axokine-treated 
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wildtype mice sustained a clear weight loss up to 13% during the injection period, 
gp130∆POMC mice only lost up to 10 % body mass during Axokine treatment. These 
observations confirm the results of centrally applied CNTF, indicating that both, 
systemic and central administration of CNTF lead to comparable short-term effects 
and that peripheral action of CNTF does not further increase the overall anorectic 
effect of CNTF. Although a persisting weight difference between Axokine-treated 
wildtype and gp130∆POMC mice during the 16-day follow-up care period was 
detectable, further experiments are necessary to sufficiently assess the contribution 
of POMC-mediated cytokine signaling to the observed long-term protection 
capacities of CNTF. 
A previous study described the utilization of a pair-fed group to differentiate the 
effects of reduced food intake versus increased energy expenditure. Interestingly, 
significant differences in body weight gain between the pair-fed- and the Axokine 
treated group indicated an effect of Axokine to increase energy expenditure (178). 
Thus, to investigate whether Axokine action on POMC neurons accounts for such 
changes in energy expenditure and hence exerts long-term protection from weight 
rebound, food intake in wildtype and gp130∆POMC mice has to be determined, and a 
pair-fed group is reasonable for a precise evaluation. Furthermore, analysis in 
metabolic chambers might be a supplementary procedure to substantiate the 
achieved results. 
 
8.4. Hypothalamic and peripheral effects of CNTF 
Additional, intriguing mechanisms for CNTF action have been described. CNTF has 
been demonstrated to induce neurogenesis in the ARC of the adult brain (181). 
Importantly, this effect appeared to be necessary for protection against the above-
mentioned weight rebound effects. Kokoeva et al. provided evidence that newly 
proliferated neurons exhibit either NPY or POMC expression (181). Therefore, one 
could speculate that CNTF’s effect on neurogenesis requires gp130 signaling in adult 
neuronal stem cells before the newborn neurons acquire either a POMC or an NPY 
phenotype. Moreover, Kokoeva et al. demonstrated that mitotic blockade of CNTF-
stimulated cell proliferation in the ARC does not affect the acute CNTF-dependent 
weight loss, but abrogates the long-term effect on body weight regulation. The 
authors suggest that the long-term effects on body weight of CNTF-treated mice 
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require functional neurogenesis in the ARC, whereas short-term effects of CNTF 
result from acute signaling in existing neurons. According to this model, the 
protective effect against weight rebound would be retained in gp130∆POMC mice, and 
long term-studies should be extended regarding neurogenesis and cell fate. 
Additionally, another recent finding underlines the important role of hypothalamic 
gp130 signaling in mediating the anorectic response to CNTF. Belsham et al. 
identified GLP-1-receptor signaling as an important mechanism downstream of 
CNTF’s central action (195). Primary neuronal cultures from the hypothalamus of 
GLP1-receptor-knockout mice completely lacked CNTF-mediated neurogenesis, 
therefore connecting the induction of CNTF-dependent neurogenesis in the 
hypothalamus to GLP-1 receptor signaling (195). 
Furthermore, GLP-1 has been shown to be a potent activator of firing of POMC cells 
in the ARC (196), thus, CNTF action in neuronal populations other than POMC 
expressing cells could be important for an additional anorectic effect mediated by 
GLP1-signaling in POMC neurons.  
Steinberg et al. recently demonstrated that an acute reduction in hypothalamic AMP-
dependent kinases (AMPK) signaling by Axokine represents a potentially important 
mechanism in mediating Axokine effects on food intake (185). Injections of Axokine 
increased arcuate nucleus STAT3 activation and reduced AMPK signaling, but did 
not alter STAT3 phosphorylation and/or AMPK activity in the PVN, the posterior 
hypothalamus or cortex (185). 
Furthermore, it has become evident that CNTF increases fatty-acid oxidation and 
reduce insulin resistance in skeletal muscle by activating AMPK (197). Intraperitoneal 
administration of CNTF enhanced activation of STAT3 and AMPK in skeletal muscle 
whereas central injection of CNTF failed to have any effect on skeletal muscle cells, 
indicating that CNTF can act independently of central mechanisms (197). Therefore, 
gp130∆POMC mice as well as mice with targeted disruption of gp130 signaling in other 
neuronal populations of the ARC and in peripheral organs will allow to define the 
contribution of organ-specific gp130 signaling to the improvement of glucose 
metabolism and sustained weight loss upon chronic CNTF treatment.  
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8.5. Disruption of gp130 provides insight to several signaling 
pathways 
Gp130∆POMC mice provide an excellent tool to dissect the primary site of other 
cytokines acting in the CNS to regulate energy homeostasis and signaling via gp130- 
dependent receptor complexes.  
Recently, Grossberg et al. also used POMC specific gp130 knockout mice to 
examine the contribution of POMC neurons to the anorectic effects of the 
proinflammatory cytokine LIF (198). Interestingly, they observed, that mice lacking 
gp130 specifically in POMC neurons failed to respond to centrally administered LIF. 
Additionally, transgenic hypothalamic explants did not release α-MSH upon LIF 
stimulation, indicating that POMC neurons also mediate the acute anorectic effects of 
centrally injected LIF, providing a mechanistic link between inflammation and food 
intake (198). 
Furthermore, the immune-regulating and acute phase-inducing cytokine IL-6 exerts 
anti-obesity effects in rodents when administered centrally, possibly by increasing 
energy expenditure (199). Although, expression of the IL-6R has been described in 
the human ARC (200) and in the hypothalamus of rats (201, 202), currently, there is 
no evidence for arcuate IL-6R expression in mice (198). Nevertheless, to define the 
neuronal population mediating the anti-obesity effects of IL-6, it will be crucial to 
analyze the effect of centrally administered IL-6 in mice with targeted disruption of 
gp130 in neuronal populations expressing the IL-6R. 
Overall, it is necessary to keep in mind, that the knockout of gp130 signaling bears a 
certain risk of misinterpretation. Thus, instead disrupting the signaling pathway of one 
specific cytokine for example by knocking out one particular receptor, in the current 
experimental approach the signaling of a whole family of cytokines is impaired. In 
that line of thought, it is surprising that ablation of gp130 from POMC cells has no 
effect on steady-state regulation of energy homeostasis, which might either indicate 
that signaling via gp130 (and thus signaling of this cytokine family) is not necessary 
for the regulation of body weight and fuel metabolism. Alternatively, since gp130 
signaling is ablated upon POMC expression, which takes place around embryonic 
day 17 in mice, it may be the case, that compensatory mechanisms play a role here. 
Notably, the developing/neonatal hypothalamus still has the capacity to compensate 
for an anorectic tone in order to promote survival of the organism. This is in contrast 
to the adult hypothalamus, since ablation of POMC or AgRP neurons during adult life 
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leads to uncontrolled hyperphagia or hypophagia, respectively (69, 70). Thus, 
generation of an inducible PomcCre line might help to rule out potential 
compensatory mechanisms that mask the real effect. 
8.6. Perspectives 
The targeted disruption of gp130 signaling provides the opportunity to investigate 
cytokine signaling in a variety of cell populations throughout the CNS, not only in the 
ARC, but also in the PVN, the DMH and other hypothalamic nuclear regions, allowing 
for the dissection of neuronal networks targeted by different cytokines to regulate 
energy homeostasis and metabolism. 
Furthermore, generation of an inducible PomcCre line might contribute to the 
differentiation of compensatory mechanisms and real effects evoked from the 
disrupted cytokine signaling. 
Additionally, the Axokine experiment has to be extended. It is necessary to determine 
food intake and to include a pair-fed group. Furthermore, metabolic chambers for the 
evaluation of energy expenditure, and assessment of glucose metabolism before, 
during and after Axokine treatment will help to identify the mechanisms underlying 
Axokine`s weight reducing effect. 
Last but not least, given that gp130 is ubiquitously expressed, not only the CNS but 
also peripheral organs provide interesting targets for analyzing the effect of disrupted 
cytokine signaling.  
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9. Summary 
Ciliary neurotrophic factor (CNTF) exerts anorectic effects by overcoming leptin 
resistance via activation of hypothalamic neurons. However, the exact site of CNTF 
action in the hypothalamus has not yet been identified. Using Cre-loxP-mediated 
recombination in vivo, the common cytokine signaling chain gp130, which is required 
for functional CNTF signaling, was selectively inactivated in proopiomelanocortin 
(POMC)-expressing neurons. POMC-specific gp130 knockout mice exhibit unaltered 
numbers of POMC cells and normal energy homeostasis under standard and high fat 
diet. Endotoxin (LPS) and stress-induced anorexia and adrenocorticotropin regulation 
were unaffected in these animals. Strikingly, the anorectic effect of centrally 
administered CNTF was abolished in POMC-specific gp130 knockout mice. 
Correspondingly, in these animals, CNTF failed to activate STAT3 phosphorylation in 
POMC neurons and to induce c-Fos expression in the paraventricular nucleus. 
Supplemental long-term studies revealed an impaired body weight reduction in 
POMC-specific gp130 knockout mice. These data reveal POMC neurons as a critical 
site of CNTF action in mediating its anorectic and body weight reducing effect.
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10. Zusammenfassung 
Der ciliare neurotrophe Faktor (CNTF) übt seine anorexigene Wirkung über die 
Aktivierung hypothalamischer Neurone aus und ist damit sogar in der Lage, eine 
bestehende Leptin-Resistenz zu überwinden. Die genaue Wirkweise von CNTF an 
Neuronen des Hypothalamus ist bislang jedoch unklar. Um den Effekt der CNTF-
Wirkung an Pro-opiomelanocortin- (POMC-) ausprägenden Neuronen des 
Hypothalamus zu untersuchen, wurde mithilfe des Cre-loxP-Systems in der Maus 
das für die CNTF-Signalkaskade notwendige Glykoprotein 130 (GP130) selektiv in 
POMC ausprägenden Neuronen inaktiviert. Die so entstandenen POMC-spezifischen 
GP130-Knockout-Mäuse wiesen sowohl unter Standardernährung als auch unter 
fettreicher Ernährung eine reguläre Anzahl an POMC-Zellen und normale Parameter 
der Energie-Homöostase auf. Die durch Endotoxin (LPS) und Stress induzierte 
Anorexie war in diesen Tieren ebenso wenig verändert, wie die Regulation von 
Adrenokortikotropin. Bemerkenswert war jedoch, dass POMC-spezifische GP130-
Knockout-Mäuse nach zentraler CNTF-Gabe eine deutlich abgeschwächte Reduktion 
der Nahrungsaufnahme zeigten. Ebenso war CNTF in diesen Tieren nicht in der 
Lage, eine STAT3-Phosphorylierung zu bewirken und c-Fos Expression im 
paraventrikulären Nukleus hervorzurufen. Zusätzliche Langzeitstudien zeigten, dass 
POMC-spezifische GP130-Knockout-Tiere im Verlauf einer systemischen CNTF-
Behandlung deutlich weniger Körpergewicht verlieren, als Wildtyp-Mäuse. Diese 
Daten verdeutlichen, dass POMC Neurone eine entscheidende Rolle in der 
Vermittlung der anorexigenen und Körpergewichts-reduzierenden Wirkung von CNTF 
spielen. 
. 
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